<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Genet</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Genet</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Genetics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-8021</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6908522</article-id>
    <article-id pub-id-type="doi">10.3389/fgene.2019.01260</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Genetics</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Otálora-Otálora</surname>
          <given-names>Beatriz Andrea</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/700123"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Florez</surname>
          <given-names>Mauro</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/700136"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>López-Kleine</surname>
          <given-names>Liliana</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/700565"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Canas Arboleda</surname>
          <given-names>Alejandra</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/700379"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Grajales Urrego</surname>
          <given-names>Diana Marcela</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/700131"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rojas</surname>
          <given-names>Adriana</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/700142"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Facultad de Medicina, Universidad Nacional de Colombia</institution>, <addr-line>Bogotá</addr-line>, <country>Colombia</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Departamento de Estadística, Grupo de Investigación en Bioinformática y Biología de sistemas – GiBBS, Facultad de Ciencias, Universidad Nacional de Colombia</institution>, <addr-line>Bogotá</addr-line>, <country>Colombia</country></aff>
    <aff id="aff3"><sup>3</sup><institution>Departamento de Medicina Interna, Hospital Universitario San Ignacio</institution>, <addr-line>Bogotá</addr-line>, <country>Colombia</country></aff>
    <aff id="aff4"><sup>4</sup><institution>Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana</institution>, <addr-line>Bogotá</addr-line>, <country>Colombia</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Seungchan Kim, Prairie View A&amp;M University, United States</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Fuhai Li, The Ohio State University, United States; Stefano Forte, Mediterranean Institute of Oncology (IOM), Italy</p>
      </fn>
      <corresp id="fn001">*Correspondence: Liliana López-Kleine, <email xlink:href="mailto:llopezk@unal.edu.co" xlink:type="simple">llopezk@unal.edu.co</email>; Adriana Rojas, <email xlink:href="mailto:rojas-adriana@javeriana.edu.co" xlink:type="simple">rojas-adriana@javeriana.edu.co</email>
</corresp>
      <fn fn-type="other" id="fn002">
        <p>This article was submitted to Bioinformatics and Computational Biology, a section of the journal Frontiers in Genetics</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>06</day>
      <month>12</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2019</year>
    </pub-date>
    <volume>10</volume>
    <elocation-id>1260</elocation-id>
    <history>
      <date date-type="received">
        <day>13</day>
        <month>8</month>
        <year>2019</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>11</month>
        <year>2019</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2019 Otálora-Otálora, Florez, López-Kleine, Canas Arboleda, Grajales Urrego and Rojas</copyright-statement>
      <copyright-year>2019</copyright-year>
      <copyright-holder>Otálora-Otálora, Florez, López-Kleine, Canas Arboleda, Grajales Urrego and Rojas</copyright-holder>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p><bold>Background:</bold> Epidemiological and clinical evidence points cancer comorbidity with pulmonary chronic disease. The acquisition of some hallmarks of cancer by cells affected with lung pathologies as a cell adaptive mechanism to a shear stress, suggests that could be associated with the establishment of tumoral processes.</p>
      <p><bold>Objective:</bold> To propose a bioinformatic pipeline for the identification of all deregulated genes and the transcriptional regulators (TFs) that are coexpressed during lung cancer establishment, and therefore could be important for the acquisition of the hallmarks of cancer.</p>
      <p><bold>Methods:</bold> Ten microarray datasets (six of lung cancer, four of lung diseases) comparing normal and diseases-related lung tissue were selected to identify hub differentiated expressed genes (DEGs) in common between lung pathologies and lung cancer, along with transcriptional regulators through the utilization of specialized libraries from R language. DAVID bioinformatics tool for gene enrichment analyses was used to identify genes with experimental evidence associated to tumoral processes and signaling pathways. Coexpression networks of DEGs and TFs in lung cancer establishment were created with Coexnet library, and a survival analysis of the main hub genes was made.</p>
      <p><bold>Results:</bold> Two hundred ten DEGs were identified in common between lung cancer and other lung diseases related to the acquisition of tumoral characteristics, which are coexpressed in a lung cancer network with TFs, suggesting that could be related to the establishment of the tumoral pathology in lung. The comparison of the coexpression networks of lung cancer and other lung diseases allowed the identification of common connectivity patterns (CCPs) with DEGs and TFs correlated to important tumoral processes and signaling pathways, that haven´t been studied to experimentally validate their role in the early stages of lung cancer. Some of the TFs identified showed a correlation between its expression levels and the survival of lung cancer patients.</p>
      <p><bold>Conclusion:</bold> Our findings indicate that lung diseases share genes with lung cancer which are coexpressed in lung cancer, and might be able to explain the epidemiological observations that point to direct and inverse comorbid associations between some chronic lung diseases and lung cancer and represent a complex transcriptomic scenario.</p>
    </abstract>
    <kwd-group>
      <kwd>lung cancer</kwd>
      <kwd>interstitial lung diseases (ILDs)</kwd>
      <kwd>pulmonary arterial hypertension (PAH)</kwd>
      <kwd>differentially expressed genes (DEGs)</kwd>
      <kwd>coexpression networks</kwd>
      <kwd>early detection and prognosis biomarkers</kwd>
      <kwd>survival</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">Pontificia Universidad Javeriana<named-content content-type="fundref-id">10.13039/501100009543</named-content></funding-source>
      </award-group>
      <award-group>
        <funding-source id="cn002">Universidad Nacional de Colombia<named-content content-type="fundref-id">10.13039/501100002753</named-content></funding-source>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="9"/>
      <table-count count="2"/>
      <equation-count count="0"/>
      <ref-count count="227"/>
      <page-count count="18"/>
      <word-count count="7346"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>Lung cancer is the leading cause of cancer death in men and women in the world (<xref rid="B160" ref-type="bibr">Siegel et al., 2015</xref>). Lung cancer is a malignant tumor of uncontrolled cell growth with the ability to metastasize in distant tissues (<xref rid="B40" ref-type="bibr">Dela Cruz et al., 2011</xref>). Lung cancer can be divided into two main histological types: non-small cell cancer (NSCLC), representing 85% of all lung cancers, and small cell cancer (SCLC) (<xref rid="B63" ref-type="bibr">Gridelli et al., 2015</xref>). The global cancer burden reported by GLOBOCAN 2018 and the International Agency for Research on Cancer estimates that there will be 18.1 million new cancer cases (<xref rid="B20" ref-type="bibr">Bray et al., 2018</xref>). Lung cancer is the most commonly diagnosed cancer (11.6% of total cases) and the leading cause of cancer death (18.4% of total deaths due to cancer), followed by breast cancer (11.6%), prostate cancer (7.1%) and colorectal cancer (6.1%) (<xref rid="B20" ref-type="bibr">Bray et al., 2018</xref>). Lung cancer is the most frequent cancer and the leading cause of cancer death in men. In women, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death, followed by colorectal and pulmonary cancer (<xref rid="B79" ref-type="bibr">IARC and Boyle, 2018</xref>). The increase in mortality rates during the last decades have been associated with a late diagnosis, which limits their potential treatment, and is evidence of the important lack of biomarkers for the development of specific treatments against the disease (<xref rid="B40" ref-type="bibr">Dela Cruz et al., 2011</xref>).</p>
    <p>The interstitial lung diseases (ILDs) are a heterogenic group of conditions with clinic, radiologic, and functional manifestations, among which the most important are anatomopathological alterations that affect alveolointerstitial structures, like the epithelium, alveolar walls, capillary endothelium and connective tissue (perilymphatic and perivascular) between the septa and the peribronchial and peribronchiolar tissue (<xref rid="B139" ref-type="bibr">Raghu et al., 2018</xref>). Environmental factors (silica dust, asbestos fibers, grain dust, bird droppings, and animals), infections, medications (anti-inflammatory, antibiotics and cardiovascular), radiation exposure, and autoimmune, granulomatous, metabolic, systemic (connective tissue) and childhood-specific diseases are between the known associated causes (<xref rid="B138" ref-type="bibr">Raghu et al., 2004</xref>; <xref rid="B126" ref-type="bibr">Nathan et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Griese et al., 2015</xref>). The ILDs can affect men and women of any age who are exposed to specific concentrations of any of the environmental factors, and/or are carriers of genetic and epigenetic factors that predispose them for the development of the disease (<xref rid="B37" ref-type="bibr">Coultas et al., 1994</xref>; <xref rid="B64" ref-type="bibr">Griese et al., 2015</xref>). The ILDs include a wide range of diffuse pulmonary disorders that often end in pulmonary fibrosis and may occur in isolation or associated with systemic diseases (<xref rid="B167" ref-type="bibr">Spagnolo et al., 2014</xref>; <xref rid="B93" ref-type="bibr">Kropski et al., 2015</xref>).</p>
    <p>In recent decades, studies have shown a possible relationship between pathological processes in lung tissue and the development of cancer. Specifically, ILDs and lung cancer share pathogenic mechanisms such as inflammation, increased resistance to apoptosis, focal hypoxia, an increase in proliferation, viability and accumulation of cells such as fibroblasts, in regions with repeated epithelial lesions (<xref rid="B3" ref-type="bibr">Archontogeorgis et al., 2012</xref>). The epithelial mesenchymal transition (EMT) process characteristic of tumor cells and essential to carrying out metastasis processes, is a phenomenon that also occurs in epithelial type II alveolar cells that are transformed into mesenchymal cells to produce fibroblasts and myofibroblasts that directly contribute to the fibrotic event in ILDs (<xref rid="B199" ref-type="bibr">Willis and Borok, 2009</xref>). In lung diseases, epithelial cells exposure to matrix metalloproteinases can lead to an increase in reactive oxygen species levels that promote myofibroblasts differentiation (<xref rid="B163" ref-type="bibr">Sokai et al., 2015</xref>). The deregulation of metalloproteinases expression associated with a defective matrix and increase levels of reactive oxygen species are also characteristic of malignancy, suggesting a relationship between the two pathologies (<xref rid="B137" ref-type="bibr">Radisky et al., 2007</xref>). Several studies suggest a possible association between other lungs diseases and lung cancer, through different physiopathogenic mechanisms. The presence of common tumorigenic processes between lung cancer and other lung diseases suggests a possible causal association in the establishment of this tumoral pathology, and that the joint transcriptomic analysis can ultimately result in identifying potential novel biomarkers/drug targets for lung cancer early diagnosis, if it is associated with the risk.</p>
    <p>Cancer Biomarkers are used in clinical practice for diagnosis, prognosis, the identification of sensitive patients, and the prediction of cancer patients response to treatment (<xref rid="B85" ref-type="bibr">Kamel and Al-Amodi, 2017</xref>). There are several types of biomarkers: Prognostic biomarkers are used to identify the patients that need treatment in the future, Predictive biomarkers direct patient’s treatment selection, and Diagnostic biomarkers contribute to the diagnosis and classification of the disease, and can be useful to monitor the therapeutic response in patients (<xref rid="B53" ref-type="bibr">Fenton et al., 2011</xref>). Cancer research has identified a significant number of predictive biomarkers for some types of cancer according to their clinical usefulness (<xref rid="B85" ref-type="bibr">Kamel and Al-Amodi, 2017</xref>). In lung cancer NSCLC have been identified some predictive biomarkers whose expression can predict the response to a specific treatment (BRCA1, TP53, and KRAS) (<xref rid="B85" ref-type="bibr">Kamel and Al-Amodi, 2017</xref>).</p>
    <p>The identification of genetic risk factors, as mutations in somatic and germ cells (<italic>EGFR</italic>, <italic>TP53</italic>, <italic>KRAS</italic>, <italic>BRAF</italic>, <italic>ERBB2</italic>, <italic>MET</italic>, <italic>STK11</italic>, <italic>PIK3CA</italic>), gene amplifications (<italic>EGFR</italic>, <italic>ERBB2</italic>, <italic>MET</italic>, <italic>PIK3CA</italic>, and <italic>NKX2</italic>), deletions (DOK2) (<xref rid="B12" ref-type="bibr">Berger et al., 2010</xref>), and presence of fusion genes (<italic>ALK/EML4</italic>) (<xref rid="B162" ref-type="bibr">Soda et al., 2007</xref>), have allowed to develop specific treatments, but although they increase the susceptibility to develop lung cancer (<xref rid="B19" ref-type="bibr">Braun et al., 1994</xref>), they have not shown a concordance with the mortality rates because their limited ability to treat patients only with the associated risk factor (<xref rid="B14" ref-type="bibr">Blanchon et al., 2006</xref>). In the postgenomic era, the biomarker identification studies have begun to take into account two important components for clarifying the etiology of the tumoral diseases: First, the great inter and intratumoral variability at the molecular and cellular level in each individual and/or population of individuals; and second, the complexity of lung cancer, in terms of the huge number of deregulated genes that have been identified with genomic studies, which highlights the complexity of cancer and generates a problem in the development of therapeutic treatments for each possible variation, that must be solved.</p>
    <p>Genomic studies such as microarrays and RNA-Seq have the ability to provide information for the identification of all groups of transcriptionally dysregulated genes involved in the modulation of biological functions and signaling pathways, describing expression patterns associated with tumor grade, differentiation state, metastatic potential, and patients’ survival, when comparing tumoral and healthy tissue (<xref rid="B193" ref-type="bibr">Wang and Liotta, 2011</xref>; <xref rid="B8" ref-type="bibr">Barretina et al., 2012</xref>; <xref rid="B49" ref-type="bibr">Eswaran et al., 2013</xref>; <xref rid="B105" ref-type="bibr">Li et al., 2017</xref>; <xref rid="B115" ref-type="bibr">Ma et al., 2019</xref>). Our research group believes that the combined bioinformatics analysis of a selected group of these studies can take advantage of all the transcriptomic knowledge generated with these technologies, finding potentially valuable information that could be applied to increase the understanding of cellular processes related to complex diseases such as cancer. This kind of analysis can help us to understand the complexity of the disease from a global perspective, through the identification of all deregulated genes that participate in the establishment of lung cancer. Additionally, the comparison of different pathologies when performing a global analysis of several databases, allow us to find specificities and common processes, which, when analyzing each study separately, cannot be detected.</p>
    <p>The study of complex systems can be based on communication between signaling pathways in gene networks, and on the identification of prognosis modules in co-expression networks associated with a biological process, which can become good targets for pharmaceutical treatment. (<xref rid="B226" ref-type="bibr">Zhou et al., 2019</xref>). Currently, published studies look for cancer biomarkers associated with the hallmarks of cancer (<xref rid="B69" ref-type="bibr">Hanahan and Weinberg, 2011</xref>), based on the generation of co-expression networks using transcriptomic studies in different types of cancer (<xref rid="B216" ref-type="bibr">Yu et al., 2019b</xref>), through the weighted gene coexpression networks (WGCNA) method, which identified more than 3,000 coexpression modules associated with tumoral processes such as cell proliferation, extracellular matrix remodeling, hypoxia, inflammation, angiogenesis, and cell differentiation (<xref rid="B81" ref-type="bibr">Ivliev et al., 2016</xref>); with Gaussian mixing models (GMM) an important number of modules in a pairwise gene comparison to reduce extrinsic background noise in the co-expression network (<xref rid="B54" ref-type="bibr">Ficklin et al., 2017</xref>); and using a permutations test, the communities present in all networks have been identified, followed by an enrichment analysis to identify the associated biological processes, and a survival analysis to differentiate communities capable of differentiating cancer patients from healthy individuals (<xref rid="B215" ref-type="bibr">Yu et al., 2019a</xref>).</p>
    <p>We propose a new methodology for the creation of co-expression networks, which was developed by Dr. López-Kleine research group, based on the use of the library “Coexnet” (<xref rid="B72" ref-type="bibr">Henao et al., 2018</xref>). This method allows the creation of co-expression networks from microarray data sets, the identification of multiple nodes connected in an intersection network in common when comparing two or several biological networks, which have been called common connectivity patterns (CCPs) (<xref rid="B72" ref-type="bibr">Henao et al., 2018</xref>). Then, Coexnet allows to create coexpresión networks of lung cancer and other lung diseases, to compare them and identify CCPs in common between pathologies, and TFs deregulated and coexpressed during the establishment of tumoral pathology in the lung. Therefore, we were able to visualize the complexity of lung cancer, as the previous methods, however, we also generate within the same bioinformatic pipeline a methodology to address the huge complexity of the disease, identifying the transcriptional regulators of all deregulated and coexpressed genes in lung cancer associated with the acquisition of the hallmarks of cancers, in order to take a reasonable number of genes as candidate biomarkers into the experimental validation phase, for the future the development of specific and personalized treatments of lung cancer.</p>
  </sec>
  <sec id="s2">
    <title>Methods</title>
    <sec id="s2_1">
      <title>Selection of Gene Expression Data</title>
      <p>Ten sets of expression data (microarrays) were selected from the public repositories Gene Expression Omnibus (GEO) from NCBI and ArrayExpress from EBI. Six sets compare tumor tissue from patients with lung cancer and normal lung tissue, and the other four sets compare lung tissue affected with different lung diseases with normal lung tissue (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). The analysis follows 3 stages: 1) Data Pre-processing (quality verification, filter, normalization, etc.) based on the methodology proposed by <xref rid="B100" ref-type="bibr">Leal et al. (2014)</xref> 2) Detection of differentially expressed genes (DEGs) (<xref rid="B130" ref-type="bibr">Oshlack et al., 2010</xref>), 3) Identification of transcription factors among DEGs detected. In the first stage, the quality of the data was evaluated in order to work with those that have acceptable experimental validity. In the second and third stage, an important number of DEGs associated with biological functions relevant to the oncogenic process were obtained from other lung diseases and lung cancer.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Analyzed data sets, each study code, subjects’ related disease, number of samples per condition and reference.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" rowspan="1" colspan="1">Study code</th>
              <th valign="top" rowspan="1" colspan="1">Subjects disease</th>
              <th valign="top" rowspan="1" colspan="1">Number of samples</th>
              <th valign="top" rowspan="1" colspan="1">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE19804</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Non-smoking women with NSCLC</td>
              <td valign="top" rowspan="1" colspan="1">Normal (60) vs. Cancer (60)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B113" ref-type="bibr">Lu et al., 2010</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE10072</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Patients with lung adenocarcinoma</td>
              <td valign="top" rowspan="1" colspan="1">Normal (49) vs. Cancer (58)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B96" ref-type="bibr">Landi et al., 2008</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE3268</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Patients with Squamous lung cancer cells</td>
              <td valign="top" rowspan="1" colspan="1">Normal (5) vs. Cancer (5)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B192" ref-type="bibr">Wachi et al., 2005</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE108055</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Typical and atypical carcinoid, and small cell lung cancer</td>
              <td valign="top" rowspan="1" colspan="1">Normal (9) vs. Cancer (54)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">Asiedu et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>E-MTAB-5231</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Patients with NSCLC</td>
              <td valign="top" rowspan="1" colspan="1">Normal (18) vs. Cancer (22)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B200" ref-type="bibr">Willuda et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>E-MTAB-3950</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Pre-invasive and Invasive Early Squamous Carcinoma</td>
              <td valign="top" rowspan="1" colspan="1">Normal (30) vs. Cancer (30)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B91" ref-type="bibr">Koper et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE21411</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Interstitial lung diseases (ILDs)</td>
              <td valign="top" rowspan="1" colspan="1">Normal (12) vs. ILD (42)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">Cho et al., 2011</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE1650</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Emphysema</td>
              <td valign="top" rowspan="1" colspan="1">Normal (12) vs. Emphysema (18)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B168" ref-type="bibr">Spira et al., 2004</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE2052</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Idiopathic pulmonary fibrosis (IPF)</td>
              <td valign="top" rowspan="1" colspan="1">Normal (11) vs. IPF (13)</td>
              <td valign="top" rowspan="1" colspan="1">(<xref rid="B131" ref-type="bibr">Pardo et al., 2005</xref>; <xref rid="B88" ref-type="bibr">Kim et al., 2006</xref>)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>GSE113439</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">Pulmonary arterial hypertension (PAH)</td>
              <td valign="top" rowspan="1" colspan="1">Normal (11) vs. PAH (15)</td>
              <td valign="top" rowspan="1" colspan="1">None publications in PubMed</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="s2_2">
      <title>Differentially Expressed Genes (DEGs) Analysis</title>
      <p>Differentially expressed genes (DEGs) identification is based on finding if there is statistical evidence to declare that a gene is more or less active in a condition (“lung pathology”) with respect to a control (“normal lung”). R language (<xref rid="B136" ref-type="bibr">R Core Team, 2019</xref>) and specialized libraries were used to identify DEGs in every selected data set. First, pre-processing and quality control of each data set was performed through exploratory analysis of the data. This analysis consisted of evaluating the similar gene expression distribution per sample and examining that there were no genes with atypical expressions or samples that had a different behavior with respect to the others, through boxplots, density plots and summary statistics. Second, normalization was conducted in each data set in order to reduce data dispersion and make samples comparable each other using Variance Stabilizing Normalization (VSN) method using VSN library (<xref rid="B78" ref-type="bibr">Huber et al., 2002</xref>; <xref rid="B58" ref-type="bibr">Gautier et al., 2004</xref>), evaluating the similar gene expression distribution per sample in boxplots and density plots to use only statistically comparable data sets. When each data set passed pre-processing and normalization steps, it proceeded with the detection of DEGs.</p>
      <p>The DEGs were selected based on the method of Significance analysis of microarray data (SAM) employing SAM function of siggenes package (<xref rid="B155" ref-type="bibr">Schwender, 2012</xref>), with the lowest error rate (q-value &lt; 0.01), and under 15% FDR (<xref rid="B182" ref-type="bibr">Tibshirani et al., 2018</xref>). The q-value (Storey’s q-value) indicates the probability that a DEG identified is a false positive, corrected by multiple tests significance. This analysis was carried out for both lung cancer (LC) and other lung diseases (LD) data sets and the DEGs list in each data set was divided into positive and negative deregulated genes according to its fold change. Finally, all common genes between LC and other LD, varying in the same sense (over-expressed or repressed in the pathology with respect to healthy tissue) in the majority, 7 of the 10 sets analyzed, (in at least five of the six lung cancer sets, and one or two of other lung disease) were established as our “winner DEGs”. These were highlighted in the functional analysis, classifying those involved in tumorigenic processes.</p>
    </sec>
    <sec id="s2_3">
      <title>Functional Annotation and Enrichment Analysis</title>
      <p>The analysis of enrichment and functional annotation allows the identification of significant and specific biologic functional categories within our list of genes, considering the current scientific knowledge and the organism. This analysis was carried out with the online DAVID tool (Bioinformatics Resources 6.8, NIAID/NIH” (<uri xlink:type="simple" xlink:href="https://david.ncifcrf.gov/summary.jsp">https://david.ncifcrf.gov/summary.jsp</uri>) (<xref rid="B42" ref-type="bibr">Dennis et al., 2003</xref>), which associates the winner DEGs found with specific biological functions. The analysis of associated diseases and functional categories for winning genes positively or negatively deregulated in the majority of sets of lung cancer and in other lung diseases, allow us to identify the DEGs with greater scientific evidence associated with oncogenic processes. The P value was corrected (because of multiple tests analyses) with Benjamini’s method (<xref rid="B10" ref-type="bibr">Benjamini and Hochberg, 1995</xref>), and it was considered a significant enrichment for functional categories P values ≤0.05. An extensive literature search in the common overregulated winner DEGs related to cancer was preformed to validated its association with lung cancer and other lung diseases.</p>
    </sec>
    <sec id="s2_4">
      <title>Coexpression Network Analysis</title>
      <p>The web-based system oPOSSUM (<uri xlink:type="simple" xlink:href="http://opossum.cisreg.ca/cgi-bin/oPOSSUM3/opossum_human_ssa">http://opossum.cisreg.ca/cgi-bin/oPOSSUM3/opossum_human_ssa</uri>) was used to detect over-represented conserved transcription factor binding sites and binding site combinations in the 45 overexpressed genes related to cancer according to DAVIDs analysis and verified with literature searching. The common 45 DEGs and the 45 TF (90 genes in total) were used to construct a gene co-expression network, a heatmap and a corrplot. The normalized expression profiles of the 59 of the 77 genes of interest were extracted from the gene expression data set GSE19804 and a similarity matrix was constructed using the absolute value of Pearson correlation. On this matrix, the threshold was identified to establish a final edge on the co-expression network using the methodology of <xref rid="B100" ref-type="bibr">Leal et al. (2014)</xref>, based on the comparison of the obtained clustering coefficient with the clustering coefficient of a random graph (<xref rid="B100" ref-type="bibr">Leal et al., 2014</xref>).</p>
      <p>The R library “Coexnet” was used to construct coexpression networks of one lung cancer data set (GSE19804) and the four sets of other lung diseases (GSE21411, GSE1650, GSE2052, GSE113439). Coexnet compared each lung disease network with the lung cancer network in order to identify common connectivity patterns (CCPs) between them, allowing the identification of molecular components linked together and common in the biological networks (<xref rid="B72" ref-type="bibr">Henao et al., 2018</xref>). CCPs networks analysis with Cytoscape (<xref rid="B159" ref-type="bibr">Shannon et al., 2003</xref>) and iRegulon application allowed the identification of transcription factors or master regulators of every CCP identified (<xref rid="B82" ref-type="bibr">Janky et al., 2014</xref>).</p>
    </sec>
    <sec id="s2_5">
      <title>Survival Analysis of Transcription Factors</title>
      <p>The effect of the expression of the hub genes or TFs identified with the transcriptomic, enrichment and coexpression analyses, in the survival of patients with lung cancer was assessed with the Kaplan Meier-plotter tool (KM plotter: <uri xlink:type="simple" xlink:href="http://kmplot.com/analysis/index.php?p=service&amp;cancer=lung">http://kmplot.com/analysis/index.php?p=service&amp;cancer=lung</uri>) (<xref rid="B67" ref-type="bibr">Gyorffy et al., 2013</xref>). KM plotter information about overall surviving (OS) is calculated and plotted with datasets from GEO, EGA and TCGA, based on hazard ratio (HR) of 95% confidence intervals and with a log rank P-value (LogrankP-value) associated.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec id="s3_1">
      <title>Differentially Expressed Genes (DEGs) in Common Between Lung Cancer and Other Lung Diseases</title>
      <p>In general, there is a greater number of DEGs in lung cancer than in other lung diseases, and a greater number of overregulated genes than downregulated genes in both groups (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). However, there is a high number of deregulated genes in Pulmonary arterial hypertension (PAH) dataset equivalent to lung cancer datasets. The identification of 395 genes that were differentially expressed in lung cancer and other lung diseases in at least seven sets of the 10 data sets analyzed, indicated that the joint microarray data sets analysis allows us to find a characteristic metafirm of lung diseases establishment processes at molecular level. 210 of the DEGs were equally deregulated in both, lung cancer and other lung diseases, among which 116 were overregulated and 94 downregulated (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table 1</bold></xref>).</p>
      <fig id="f1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Differentially expressed genes (DEGs) in lung cancer and other lung diseases studies. The image was made using GraphPad Prism version 8.00 for Windows, GraphPad Software, La Jolla California USA, <uri xlink:type="simple" xlink:href="http://www.graphpad.com/">www.graphpad.com</uri>.</p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g001"/>
      </fig>
    </sec>
    <sec id="s3_2">
      <title>Functional Annotation and Enrichment Analysis</title>
      <p>The downregulated “winner” DEGs are associated with angiogenesis, cell adhesion and the negative regulation of transcription from RNA polymerase II promoter (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>). The overregulated “winner” DEGs are associated with several cell cycle processes (<xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>), DNA replication, mismatch repair, and p53 signaling pathways (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>). The functional annotation analysis of the 116 overregulated common genes identified 45 genes associated with cancer with a significant corrected P value.</p>
      <fig id="f2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Biological processes associated to downregulated genes common in lung cancer and other lung diseases. The image was made using GraphPad Prism version 8.00 for Windows, GraphPad Software, La Jolla California USA, <uri xlink:type="simple" xlink:href="http://www.graphpad.com/">www.graphpad.com</uri>.</p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g002"/>
      </fig>
      <fig id="f3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Biological processes associated with common overregulated genes in lung cancer and other lung diseases. The image was made using GraphPad Prism version 8.00 for Windows, GraphPad Software, La Jolla California USA, <uri xlink:type="simple" xlink:href="http://www.graphpad.com/">www.graphpad.com</uri>. </p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g003"/>
      </fig>
      <fig id="f4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Signaling pathways associated with common overregulated genes in lung cancer and other lung diseases. The image was made using GraphPad Prism version 8.00 for Windows, GraphPad Software, La Jolla California USA, <uri xlink:type="simple" xlink:href="http://www.graphpad.com/">www.graphpad.com</uri>. </p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g004"/>
      </fig>
    </sec>
    <sec id="s3_3">
      <title>Coexpression Network Analysis</title>
      <p>The heatmap and corrplot show The coexpression network created with the 45 DEGs associated with cancer in DAVIDs enrichment analysis and the 45 TFs identified with Opossum as their possible regulators, has 35 DEGs coexpressed with four TFs (YY1, ZEB1, E2F1, and NR4A2) (<xref ref-type="fig" rid="f5"><bold>Figure 5</bold></xref>) (<xref rid="B159" ref-type="bibr">Shannon et al., 2003</xref>). The heatmap and corrplot show the correlation between all the genes used to create the network (<xref ref-type="fig" rid="f6"><bold>Figures 6</bold></xref> and <xref ref-type="fig" rid="f7"><bold>7</bold></xref>). YY1 is overregulated in three lung cancer datasets and downregulated in PAH dataset. NR4A2 is downregulated in five lung cancer datasets and overregulated in PAH dataset. ZEB1 is downregulated in four lung cancer and ILDs datasets, and overregulated in PAH. E2F1 is only overexpressed in five lung cancer datasets. The extensive literature search associates most of the coexpression network genes with lung cancer, and most of them with other lung diseases (<xref ref-type="supplementary-material" rid="SM2"><bold>Supplementary Table 2</bold></xref>). 36 genes of the coexpression network were deregulated in PAH, 12 genes in IPF, 1 in ILDs, and 1 in emphysema dataset, but none was reported or analyzed in their specific lung disease study.</p>
      <fig id="f5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Coexpression network of overregulated genes common in lung cancer and other lung diseases (LC&amp;LD coexpression network). The red circles show the TFs coexpressed in the network.</p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g005"/>
      </fig>
      <fig id="f6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Heatmap of the winner deregulated genes common in lung cancer and other lung diseases.</p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g006"/>
      </fig>
      <fig id="f7" position="float">
        <label>Figure 7</label>
        <caption>
          <p>Corrplot of the winner deregulated genes common in lung cancer and other lung diseases.</p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g007"/>
      </fig>
      <p>Furthermore, the coexpression network genes were related with the seven of the 10 Hallmarks of Cancer proposed by <xref rid="B69" ref-type="bibr">Hanahan and Weinberg
(2011)</xref> (<xref ref-type="fig" rid="f8"><bold>Figure 8</bold></xref>). NR4A2 and E2F1 function have been related with resisting to cell death and sustaining a proliferative signal processes in lung cancer. Meanwhile, YY1 and ZEB1 function have been related with the activation of invasion and metastasis processes (<xref ref-type="fig" rid="f8"><bold>Figure 8</bold></xref>). Most of the coexpression network genes carry out their function in the nucleus, some in the endoplasmic reticulum and the cytoskeleton. Additionally, the functional annotation of the coexpressed genes of the network showed an important association with cancer and the same signaling pathways of the overregulated genes in common between lung cancer and other lung diseases, with significant P values.</p>
      <fig id="f8" position="float">
        <label>Figure 8</label>
        <caption>
          <p>Hallmarks of cancer related to the genes of the LC&amp;LD coexpression network.</p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g008"/>
      </fig>
      <p>The library Coexnet was able to find a CCP in every comparison between the coexpression networks of the lung cancer study and the other lung diseases studies. The CCP of lung cancer and ILDs has 15 nodes and 99 edges, the CCP of lung cancer with emphysema has 185 nodes and 15,954 edges, the CCP of lung cancer and IPF has 353 nodes and 60,696 edges, and the CCP of lung cancer and PAH has 3,389 nodes and 5,537,212 edges. DAVIDs analysis of the genes in every CCP showed important associations of LC-IPF CCP with biological processes related with the acquisition of tumoral characteristics, and the LC-PAH CCP with deregulation in metabolism and signaling pathways related to inflammatory processes in cancer. The Cytoscape network analysis showed that the CCPs are highly interconnected (<xref ref-type="supplementary-material" rid="SM3"><bold>Supplementary Table 3</bold></xref>), and highly associated with important signaling pathways deregulated in cancer, and regulated by specific TFs found in our joint transcriptomic analysis.</p>
    </sec>
    <sec id="s3_4">
      <title>Survival Analysis of Transcription Factors</title>
      <p>The KM plotter analysis for the transcription factors identified during the present study revealed a statistically significant association between the expression levels of YY1 and NR4A2 with the survival of lung cancer patients (<xref ref-type="fig" rid="f9"><bold>Figure 9</bold></xref>) (<xref rid="B67" ref-type="bibr">Gyorffy et al., 2013</xref>). The multivariate analysis showed association of some of the transcription factors expression with the stage, and smoking history of lung cancer patients (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>).</p>
      <fig id="f9" position="float">
        <label>Figure 9</label>
        <caption>
          <p>KM plots of the TFs associated with the survival of lung cancer patients. <bold>(A)</bold> YY1, <bold>(B)</bold> NR4A2.</p>
        </caption>
        <graphic xlink:href="fgene-10-01260-g009"/>
      </fig>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Kaplan–Meier multivariate analysis of transcription factors.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" rowspan="2" colspan="1">Variable</th>
              <th valign="top" colspan="2" rowspan="1">NR4A2</th>
              <th valign="top" colspan="2" rowspan="1">YY1</th>
            </tr>
            <tr>
              <th valign="top" rowspan="1" colspan="1">P value</th>
              <th valign="top" rowspan="1" colspan="1">Hazard ratio</th>
              <th valign="top" rowspan="1" colspan="1">P value</th>
              <th valign="top" rowspan="1" colspan="1">Hazard ratio</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>Grade</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">0.2562</td>
              <td valign="top" rowspan="1" colspan="1">0.75 (0.46–1.23)</td>
              <td valign="top" rowspan="1" colspan="1">0.7319</td>
              <td valign="top" rowspan="1" colspan="1">1.09 (0.68–1.74)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>Stage</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">0.0533</td>
              <td valign="top" rowspan="1" colspan="1">0.4 (0.16–1.01)</td>
              <td valign="top" rowspan="1" colspan="1">0.1776</td>
              <td valign="top" rowspan="1" colspan="1">0.51 (0.19–1.36)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>AJCC stage T</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">0.0417</td>
              <td valign="top" rowspan="1" colspan="1">1.8 (1.02–3.16)</td>
              <td valign="top" rowspan="1" colspan="1">0.0973</td>
              <td valign="top" rowspan="1" colspan="1">1.62 (0.92–2.88)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>AJCC stage N</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">0.0103</td>
              <td valign="top" rowspan="1" colspan="1">3.14 (1.31–7.52)</td>
              <td valign="top" rowspan="1" colspan="1">0.0505</td>
              <td valign="top" rowspan="1" colspan="1">2.53 (1–6.44)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>Gender</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">0.1274</td>
              <td valign="top" rowspan="1" colspan="1">1.52 (0.89–2.61)</td>
              <td valign="top" rowspan="1" colspan="1">0.187</td>
              <td valign="top" rowspan="1" colspan="1">1.45 (0.84–2.51)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>Smoking</bold>
                <bold>history</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">0.5075</td>
              <td valign="top" rowspan="1" colspan="1">1.65 (0.37–7.34)</td>
              <td valign="top" rowspan="1" colspan="1">0.5089</td>
              <td valign="top" rowspan="1" colspan="1">1.65 (0.37–7.31)</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">
                <bold>Survival</bold>
              </td>
              <td valign="top" rowspan="1" colspan="1">0.0043</td>
              <td valign="top" rowspan="1" colspan="1">–</td>
              <td valign="top" rowspan="1" colspan="1">0.0066</td>
              <td valign="top" rowspan="1" colspan="1">–</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>Recent cancer studies have shown that it manifests as abnormal expression patterns of a significant number of genes, allowing the identification of more than 450 genetic variations through extensive GWAS association analysis (<xref rid="B169" ref-type="bibr">Stadler et al., 2010</xref>). The main genetic biomarkers identified have been associated with the increased risk of developing cancer (<xref rid="B175" ref-type="bibr">Sud et al., 2017</xref>). However, pharmaceutical gene expression regulation has not contributed significantly to stop and/or reverse tumor expansion in all patients affected with the tumoral pathology in the lung (<xref rid="B39" ref-type="bibr">Das et al., 2015</xref>). The great complexity of cancer etiology represented in the significant number of dysregulated genes identified, generates an intricate problem for therapeutic treatments development since it cannot be directed to each and every one of them (<xref rid="B63" ref-type="bibr">Gridelli et al., 2015</xref>). Moreover, until now, no biomarker has shown the ability to characterize the pathology, always reversing the tumor process in all patients affected.</p>
    <p>Currently, neoplasms research has highlighted the ability of transcription factors (TFs) to regulate the expression of a large number of genes, which participate as important terminal regulators, being points of convergence in oncogenic signaling pathways; therefore, becoming promising biomarkers for cancer therapies (<xref rid="B208" ref-type="bibr">Yeh et al., 2013</xref>). TFs are important for cell differentiation during embryogenesis, but when they are deregulated in adult tissue abnormally activate signaling pathways related to tumor phenotype acquisition (<xref rid="B23" ref-type="bibr">Cameron and Neil, 2004</xref>). The LC&amp;LD coexpression network analysis created with the DEGs identified with DAVIDs-Opossum analysis allowed the identification of 4 TFs capable to regulate and important number of the 35 DEGs found in common between lung cancer and other lung diseases (<xref ref-type="fig" rid="f5"><bold>Figure 5</bold></xref>). LC&amp;LD network represent the genes with strongest experimental evidence about its association with tumorigenic processes, that could be associated with early stages of lung cancer, as they are also deregulated in other lung diseases. On the other hand, the CCPs found in common between lung cancer and other lung diseases, comparing lung cancer (LC) and other lung diseases (LD) coexpression networks represent another approximation that allows to find new hub genes that could be even more important for lung cancer establishment than those previously studied, because these are highly and equally connected and deregulated genes coexpressed in lung cancer and other lung diseases. For every CCP a transcription factor that regulates and important number of genes in the subnetwork was identified.</p>
    <p>The four TFs (YY1, ZEB1, NR4A2 and E2F1) found coexpressed and identified with the DAVID-Opossum analysis have evidence of its association with tumorigenic processes, that could relate them to establishment of lung cancer. YY1 is a highly multifunctional transcription factor that promotes cell proliferation and invasion in lung cancer cells (<xref rid="B77" ref-type="bibr">Huang et al., 2017</xref>), and EMT in H1155 cells (<xref rid="B57" ref-type="bibr">Gao et al., 2018</xref>). YY1 has been associated with a regulatory loop with cancer stem cell transcription factors (SOX2, OCT4, BMI1) during the cross-talk between the NF-kB/PI3K/AKT pathways (<xref rid="B87" ref-type="bibr">Kaufhold et al., 2016</xref>). Therefore, YY1 overexpression in lung cancer might suggest an association of these transcription factor in driving tumorigenic processes and the acquisition of stem-like characteristics in early stages of lung cancer. YY1 is directly connected with SHMT2, a gene that support tumorigenesis (<xref rid="B119" ref-type="bibr">Mattaini et al., 2016</xref>), stimulates proliferation of c-Myc deficient cells (<xref rid="B35" ref-type="bibr">Cooper et al., 2003</xref>) and increases lung tumors growth (<xref rid="B217" ref-type="bibr">Zhang et al., 2012</xref>; <xref rid="B103" ref-type="bibr">Lee et al., 2014</xref>; <xref rid="B41" ref-type="bibr">DeNicola et al., 2015</xref>; <xref rid="B220" ref-type="bibr">Zhang et al., 2017</xref>). SHMT2 is overexpressed in all LC datasets, IPF and PAH datasets.</p>
    <p>ZEB1 represses E-cadherin promoter, induces EMT by recruiting SMARCA4/BRG1 (<xref rid="B147" ref-type="bibr">Sánchez-Tilló et al., 2010</xref>), and promotes tumorigenicity by repressing stemness-inhibiting microRNAs (<xref rid="B198" ref-type="bibr">Wellner et al., 2009</xref>). ZEB1 expression has been related to early stage IB of NSCLC, tumor-node-metastasis stage, and EMT (<xref rid="B98" ref-type="bibr">Larsen et al., 2016</xref>). ZEB1 also has a tumor suppressive role, independent of its ability to induce EMT, given that ZEB1 is able to induce EMT in both KRAS- and EGFR mutant cell lines (<xref rid="B210" ref-type="bibr">Yochum et al., 2009</xref>). Therefore, ZEB1 downregulation in lung cancer could be related to its ability to inhibit tumor growth, which should be important to maintain in early stages of lung cancer. ZEB1 interacts with FEN1 and NR4A2, the third transcription factor coexpressed in LC&amp;LD coexpression network. FEN1 is an enzyme that removes the 5 ‘ends during DNA repair, processes the 5’ ends of the Okazaki fragments during DNA replication (<xref rid="B183" ref-type="bibr">Tishkoff et al., 1997</xref>). FEN1 is an endonuclease XPG/RAD2 essential for DNA replication and the protection of the genome against mutations (<xref rid="B62" ref-type="bibr">Gordenin et al., 1997</xref>). FEN1 promotes tumor progression (<xref rid="B70" ref-type="bibr">He et al., 2017a</xref>), proliferation and poor prognosis of NSCLC (<xref rid="B221" ref-type="bibr">Zhang et al., 2018a</xref>). FEN1 is overexpressed in all LC datasets and PAH dataset. YY1 and ZEB1 also appeared as the regulators of the CCP formed between LC and Emphysema, giving another layer of evidence of their importance in the establishment of LC in patients with an emphysema antecedent.</p>
    <p>NR4A2 transcriptionally regulates cell proliferation, apoptosis, inflammation, neuronal development, and carcinogenesis (<xref rid="B148" ref-type="bibr">Safe et al., 2013</xref>; <xref rid="B149" ref-type="bibr">Safe et al., 2016</xref>). NR4A2 overexpression blocks p53 target genes activation, like mir-34a, which rescues cells from p53-induced inhibition of proliferation (<xref rid="B9" ref-type="bibr">Beard et al., 2016</xref>). NR4A2 is downregulated in lung cancer and overexpressed in PAH dataset, suggesting an association with tumoral processes during early stages of lung cancer related to this lung disease. NR4A2 only interacts with ZEB1, the second transcription coexpressed in the network, which might suggest a possible coregulatory relationship between these two transcription factors and the association with the same tumorigenic processes related with ZEB1.</p>
    <p>E2F1 is a transcription activator overexpressed in lung adenocarcinoma and squamous cell lung carcinoma tissues, associated with cellular proliferation by counteracting the negative effects of cyclin-cdk inhibitors (<xref rid="B50" ref-type="bibr">Eymin et al., 2001</xref>). ANKRD22 promotes progression of NSCLC through transcriptional up-regulation of E2F1 (<xref rid="B209" ref-type="bibr">Yin et al., 2017</xref>). E2F1 was one the transcription factor that Opossum selected as possible regulator of the 45 common genes overregulated and related to cancer, and appeared in the coexpression network, even when it is not deregulated in the selected sets of other lung diseases, probably suggesting its importance at the end of early stages of lung cancer. Moreover, E2F1 was the TF identified as the most important regulator with iRegulon for the LC&amp;LD coexpression network, in terms of enrichment if its TFBS, and the number of network targets that can regulate. E2F1 interacts with SHMT2 like YY1, and RAD54L. RAD54L is a recombinational DNA repair protein, and a double-stranded DNA-dependent ATPase that stimulates homologous recombination, inducing a DNA topological changes and induces DNA repair of DNA double-strand breaks (<xref rid="B179" ref-type="bibr">Swagemakers et al., 1998</xref>; <xref rid="B144" ref-type="bibr">Ristic et al., 2002</xref>; <xref rid="B161" ref-type="bibr">Sigurdsson et al., 2002</xref>). RAD54L is upregulated in NSCLC and associated with dsDNA break repair (<xref rid="B188" ref-type="bibr">Välk et al., 2011</xref>). RAD54L is overexpressed in all lung cancer datasets and PAH dataset.</p>
    <p>The CCP formed between LC and ILD is regulated by IRF1, a transcriptional regulator of cellular responses, during hematopoiesis, inflammation, immune responses, cell proliferation and differentiation (<xref rid="B146" ref-type="bibr">Romeo et al., 2002</xref>). IRF1 regulation is associated with cell cycle, induction of growth arrest and programmed cell death following DNA damage (<xref rid="B18" ref-type="bibr">Bowie et al., 2008</xref>). IRF1 is downregulated in lung cancer, IPF and PAH datasets, probably because it represses the expression of genes involved in anti-proliferative response, such as BIRC5/survivin, CCNB1, CCNE1, CDK1, CDK2 and CDK4 (<xref rid="B4" ref-type="bibr">Armstrong et al., 2012</xref>) and in immune response, such as FOXP3, IL4, ANXA2 and TLR4 (<xref rid="B55" ref-type="bibr">Fragale et al., 2014</xref>). IRF1 stimulates p53/TP53-dependent transcription, improving EP300 recruitment which leads to an increase of p53/TP53 acetylation (<xref rid="B44" ref-type="bibr">Dornan et al., 2004</xref>). IRF1 is also known as tumor suppressor, capable to avoid tumor cell growth (<xref rid="B17" ref-type="bibr">Bouker et al., 2005</xref>), and stimulate an immune response against tumor cells (<xref rid="B181" ref-type="bibr">Tanaka et al., 1996</xref>).</p>
    <p>The CCP formed between LC and IPF is regulated by NF1, a Ras‐GTPase activating protein, which function as negative regulators for Ras proteins (<xref rid="B7" ref-type="bibr">Ballester et al., 1990</xref>), preventing the downstream activation of Ras effector pathways, MAPK and PI3K/Akt/mTOR pathways that drive the pro-proliferation, survival, differentiation (<xref rid="B201" ref-type="bibr">Xu et al., 1990</xref>; <xref rid="B16" ref-type="bibr">Bollag and McCormick, 1991</xref>), cell adhesion, and migration (<xref rid="B94" ref-type="bibr">Kweh et al., 2009</xref>). NF1 is a mutated tumor suppressor in both of the NSCLC subtypes, adenocarcinoma (<xref rid="B34" ref-type="bibr">Collisson et al., 2014</xref>) and squamous cell (<xref rid="B68" ref-type="bibr">Hammerman et al., 2012</xref>). Lung cancers with NF1 mutations have also been characterized by downstream activation of Ras signaling (<xref rid="B141" ref-type="bibr">Redig et al., 2016</xref>). Therefore, there is evidence that suggest that NF1 mutations in lung cancer con also activate Ras signaling pathway, playing a key role in the incorrect signal transduction, proliferation and malignant transformation (<xref rid="B143" ref-type="bibr">Reuter et al., 2000</xref>). The CCP formed between LC and PAH is regulated by BRCA1, a E3 ubiquitin-protein ligase that mediates ‘Lys-6’-linked polyubiquitin chains formation, enabling cellular responses to DNA damage during DNA repair (<xref rid="B102" ref-type="bibr">Lee et al., 2000</xref>; <xref rid="B194" ref-type="bibr">Wang et al., 2007</xref>). BRCA1 has a tumor suppressor function related to the transcriptional regulation to maintain genomic stability, which is directly related to hereditary breast cancer (<xref rid="B104" ref-type="bibr">Li and Greenberg, 2012</xref>; <xref rid="B156" ref-type="bibr">Sedic et al., 2015</xref>). However, BRCA1 is overregulated in LC and PAH, and it expression has been related to the occurrence and development processes of NSCLC (<xref rid="B177" ref-type="bibr">Sun et al., 2018b</xref>).</p>
    <p>The probability of surviving was associated with the expression of two transcription factors (YY1 and NR4A2) (<xref ref-type="fig" rid="f9"><bold>Figure 9</bold></xref>) identified with the coexpression analysis. Moreover, the Kaplan–Meier Multivariate analysis also associate their expression with stage, gender and smoking history. Therefore, the clinical history of patients could help in the future to prevent or apply most accurate treatments to lung cancer patients. At the moment, the clinical data highlights that risk of developing lung cancer is 1.5 times higher in patients with ILD compared with COPD and with the general population (<xref rid="B84" ref-type="bibr">Jung et al., 2011</xref>), while lung cancer prevalence in IPF patients can reach 48% (<xref rid="B99" ref-type="bibr">Le Jeune et al., 2007</xref>).</p>
    <p>Most of the genes in the LC&amp;LD coexpression network are deregulated in PAH and some in IPF, and only one in ILDs and Emphysema (<xref ref-type="supplementary-material" rid="SM2"><bold>Supplementary Table 2</bold></xref>). The pathogenesis of PAH has been associated with genetic factors that confer a predisposition for development or progression, such as mutations of the bone morphogenic receptor type II gene (BMPR2), a member of the transforming growth factor superfamily TGF-β (<xref rid="B128" ref-type="bibr">Newman et al., 2001</xref>), mutations in the activin A receptor type II 1 (ACVRL1) (<xref rid="B60" ref-type="bibr">Girerd et al., 2010</xref>), endoglin (ENG) (<xref rid="B26" ref-type="bibr">Chaouat et al., 2004</xref>), SMAD9, caveolin-1 (CAV1) and KCNK3 (<xref rid="B114" ref-type="bibr">Ma et al., 2013</xref>). The majority of BMPR2 mutations result in a loss of function, but show low penetrance (∼20%) in more than 70% of patients with familial PAH and in 11–40% of patients with sporadic PAH, affecting only 20% of carriers during their lifetime (<xref rid="B97" ref-type="bibr">Lane et al., 2000</xref>; <xref rid="B116" ref-type="bibr">Machado et al., 2001</xref>). However, BMPR2 is one of the “guardians” of pulmonary vessels homeostasis during repair processes, controlling both apoptosis and cell proliferation of pulmonary vascular smooth muscle and endothelial cells (<xref rid="B123" ref-type="bibr">Morrell, 2006</xref>). Therefore, epigenetic studies have begun to study the regulatory mechanisms associated with BMP signaling in abnormal BMPR2 function, without necessarily implying a mutation in the BMPR2 gene, such as, for example, the importance of BMP/TGF-β signaling in maintaining normal pulmonary arteriolar structure (<xref rid="B184" ref-type="bibr">Trembath et al., 2001</xref>; <xref rid="B125" ref-type="bibr">Nasim et al., 2011</xref>), STAT3/miRNA-17-92 axis activation in normal human lung endothelial cells after interleukin (IL) -6 exposure (<xref rid="B21" ref-type="bibr">Brock et al., 2009</xref>), leads to the development of PAH (<xref rid="B170" ref-type="bibr">Steiner et al., 2009</xref>), and angiobliterant vascular remodeling and robust hypertrophy of the right ventricle (<xref rid="B61" ref-type="bibr">Gomez-Arroyo et al., 2012</xref>). Overexpression of miR-17 increases the proliferation of smooth muscle cells of human pulmonary arteries, and its inhibition improves pulmonary and cardiac function (<xref rid="B134" ref-type="bibr">Pullamsetti et al., 2012</xref>). The miR-204 is negatively regulated in the smooth muscle cells of the pulmonary artery isolated from patients with PAH, and an apoptosis-resistant phenotype in smooth muscle cells is associated with induction (<xref rid="B38" ref-type="bibr">Courboulin et al., 2011</xref>).</p>
    <p>Patients with pulmonary arterial hypertension (PAH) have a sustained elevation of resistance and pulmonary arterial pressure, which makes them increasingly narrow until they are completely blocked (<xref rid="B122" ref-type="bibr">Montani et al., 2013</xref>), leading to the pumping of blood by the heart weakens the muscles until they reach heart failure through the right ventricle (<xref rid="B15" ref-type="bibr">Bogaard et al., 2009</xref>). Likewise, PAH is characterized by vascular remodeling in the three layers (intimate, middle and adventitia) of the wall of small and medium pulmonary arterioles (&lt;500 µm), in response to continuous vascular lesions that lead to abnormal muscle muscularization of distal and medial capillary arteries, loss of precapillary arteries, and thickening of arterial walls (<xref rid="B65" ref-type="bibr">Guignabert and Dorfmuller, 2013</xref>). PAH begins to develop under constant stress conditions such as inflammation and pseudo-hypoxia, initially inducing the death of endothelial cells (<xref rid="B65" ref-type="bibr">Guignabert and Dorfmuller, 2013</xref>). However, cells eventually acquire hyperproliferative abilities (<xref rid="B101" ref-type="bibr">Lee et al., 1998</xref>), associated with instability of short sequences of microsatellite DNA within plexiform lesions (<xref rid="B206" ref-type="bibr">Yeager et al., 2001</xref>), and the presence of somatic chromosomal abnormalities in the lung patients with PAH (<xref rid="B1" ref-type="bibr">Aldred et al., 2010</xref>); a deregulated cell metabolism (<xref rid="B202" ref-type="bibr">Xu et al., 2007</xref>; <xref rid="B1" ref-type="bibr">Aldred et al., 2010</xref>; <xref rid="B178" ref-type="bibr">Sutendra et al., 2010</xref>; <xref rid="B187" ref-type="bibr">Tuder et al., 2012</xref>), with reduced oxygen consumption, reduced mitochondrial respiration and increased glycolytic metabolism (<xref rid="B202" ref-type="bibr">Xu et al., 2007</xref>); and the ability to evade apoptosis (<xref rid="B118" ref-type="bibr">Masri et al., 2007</xref>), with an increase in the expression of important anti-apoptotic genes such as Bcl-xL, Bcl-2 and survivin (<xref rid="B121" ref-type="bibr">McMurtry et al., 2005</xref>; <xref rid="B185" ref-type="bibr">Tu et al., 2012</xref>); in clones of fibroblasts, smooth muscle cells (PASMC) and endothelial cells of the pulmonary arteries (PAEC), which allows vascular remodeling during PAH (<xref rid="B66" ref-type="bibr">Guignabert et al., 2013</xref>).</p>
    <p>The hypothesis of establishment or “quasi-malignancy” is also associated with the concept of an angiogenic/stem cell tumor (CSC) niche (<xref rid="B140" ref-type="bibr">Rai et al., 2008</xref>). Precursor cells can divide and migrate to pulmonary vascular adventitia through the vasa vasorum (<xref rid="B48" ref-type="bibr">Ergün et al., 2011</xref>; <xref rid="B207" ref-type="bibr">Yeager et al., 2011</xref>), and stem cells of small microvascular pulmonary endothelial cells of small arteries can proliferate to the point of obliteration (<xref rid="B2" ref-type="bibr">Alvarez et al., 2008</xref>). The pathobiological model of intraluminal angioproliferation is based on the growth of endothelial cells in PAH, where the “endothelial cell monolayer law” has been broken in favor of a tumor-like intraluminal growth (<xref rid="B186" ref-type="bibr">Tuder et al., 2001</xref>; <xref rid="B151" ref-type="bibr">Sakao et al., 2005</xref>). The endothelial cell such as the cell that initiates a complex lesion can come from three possible sources of proliferating endothelial cells: (1) An endothelial cell similar to a stem cell that is resistant to apoptosis and grows after neighboring monolayer cells intimate have been injured and have died (<xref rid="B211" ref-type="bibr">Yoder et al., 2007</xref>), (2) A precursor cell derived from the bone marrow (<xref rid="B150" ref-type="bibr">Sahara et al., 2007</xref>), and (3) An endothelial cell derived from the vascular endothelial growth factor (VEGF) action in dendritic cell-directed transdifferentiation (<xref rid="B171" ref-type="bibr">Steinman and Banchereau, 2007</xref>). The complex vascular lesions of PAH are governed by some, but not all, cancer characteristics. Therefore, although the lesions are not completely tumor, they are certainly neoplasms in the sense that there is a process of abnormal and uncontrolled cell growth.</p>
    <p>Pulmonary arterial hypertension (PAH) showed great complexity as did cancer, something that could be evidenced by the large number of DEGs, comparable to those observed in lung cancer, which may be partly explained by PAH is so difficult to treat. Vasodilator-based treatments have not demonstrated the ability to reverse vascular remodeling and do not affect survival (<xref rid="B95" ref-type="bibr">Lajoie et al., 2016</xref>), but the acquisition of cancer characteristics in PAH-associated cells suggests the potential use of anticancer drugs in patients with PAH, such as imatinib, a tyrosine kinase inhibitor, which could potentially be beneficial in patients with PAH after evaluation of potential side effects for safe use in clinical practice (<xref rid="B74" ref-type="bibr">Hoeper et al., 2013</xref>).</p>
  </sec>
  <sec sec-type="conclusions" id="s5">
    <title>Conclusion</title>
    <p>In the present work, we show how the re-analysis of gene expression data available in the databases within an organized and focused bioinformatic pipeline can be used to obtain new knowledge and give more evidence that supports a biological hypothesis, as well as find potential biomarkers associated with molecular functions in common for different diseases. The methodology we propose for the identification of the transcriptional regulators of all deregulated genes related to the acquisition of the hallmarks of cancer during lung tumorogénesis, allowed us to truly visualize the massive complexity of lung cancer. The transcriptomic analyzes of multiple gene expression data and the creation and comparison of coexpression networks allowed to identify all the genes involved and the molecular events associated with the lung tumoral process, and the transcription factors or regulators of all these genes that can participate in the establishment of the disease, as biomarkers, which will lead in the future to establish in each patient the specific molecular event that causes the pathology, and to implement an effective personalized therapy against lung cancer.</p>
    <p>The existence of common DEGs among different lung pathologies strengthens the experimental evidence that supports the hypothesis about a possible causal relationship between different lung diseases and lung cancer, because the deregulated biological functions in other lung diseases are related with oncogenic processes, and may be the first functions affected and those necessary for the establishment of a tumor pathology. Therefore, this group of genes can be more specific for the early stages of lung cancer, and might be more useful for early detection, and eventually could be integrated into the clinical practice to increase early detection probability of lung cancer, and used in the development of personalized therapies. The TFs coexpressed in the LC&amp;LD network and the CCPs LC–LD have experimental evidence of their association with the acquisition of hallmarks of cancer during its establishment that must be validated experimentally. Common DEGs and TFs among lung pathologies might have the potential to be used as possible biomarkers for diagnosis and treatment that should be evaluated experimentally in patients, to demonstrate that its deregulation is crucial for the initiation and establishment of the tumor process in the lung, and therefore, the regulation of its expression is sufficient to prevent, control and revert the tumor process in a more efficient and specific way in every patient.</p>
    <p>The levels of expression of the TFs associated with the establishment of lung according to our joint transcriptomic and coexpression analysis must be evaluated experimentally, along with the expression of the winner DEGs coexpressed in lung cancer. Functional analysis must be performed for every TF and winner DEGs to establish the association with the acquisition of which hallmark of cancer are related. Moreover, all functional and direct targets of every TF identified in lung cancer must be identified to fully understand their regulatory function during early stages of the disease. Also, the TFs identified as the key regulators for its ability to control and reverse the tumor process must be studied in depth, to find the regulatory mechanisms associated with their expression in lung cancer, like histone modifications, DNA methylation and non-coding RNAs, as the basis to develop specific and effective techniques of early detection and treatments against the tumoral pathology of the lung.</p>
    <p>The joint transcriptomic laid the foundation to guide the research field of our lab providing potential candidate biomarkers that must be experimentally validated within the all regulatory transcriptional network of lung cancer, to become prognostic, diagnostic, and predictor biomarkers of lung cancer, which in the future will also guide the clinician process to establish the specific molecular event that causes a tumoral pathology in each patient, and to implement an effective personalized therapy against the disease.</p>
  </sec>
  <sec sec-type="data-availability" id="s6">
    <title>Data Availability Statement</title>
    <p>All microarray data sets are available for the scientific community, in the Gene Expression Omnibus (GEO) and ArrayExpress.</p>
  </sec>
  <sec id="s7">
    <title>Author Contributions</title>
    <p>LL-K proposed the combined analysis to identify common genes between pathologies, the step-by-step methodology applied and led the process of data analysis. MF did the data pre-processing and the detection of differentially expressed genes (DEGs) using specific libraries in R. BO-O did the functional/enrichment analysis, the literature searching, the coexpression network and survival analysis, and contribute with the manuscript writing. DU contributed with the literature searching of other lung diseases. AR and AA contributed to the study conception and design, leading the results interpretation and making important contributions to the <italic>Discussion</italic> section. All authors critically reviewed and approved final manuscript and agree to be accountable for all aspects of the work.</p>
  </sec>
  <sec sec-type="funding-information" id="s8">
    <title>Funding</title>
    <p>The current article was funded by the grant number 41492 from Universidad Nacional de Colombia, and PUJ ID7687 from Pontificia Universidad Javeriana.</p>
  </sec>
  <sec id="s9">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
</body>
<back>
  <sec sec-type="supplementary-material" id="s10">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2019.01260/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2019.01260/full#supplementary-material</ext-link>
</p>
    <supplementary-material content-type="local-data" id="SM1">
      <media xlink:href="Table_1.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM2">
      <media xlink:href="Table_2.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM3">
      <media xlink:href="Table_3.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldred</surname><given-names>M. A.</given-names></name><name><surname>Comhair</surname><given-names>S. A.</given-names></name><name><surname>Varella-Garcia</surname><given-names>M.</given-names></name><name><surname>Asosingh</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Noon</surname><given-names>G. P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>182</volume>, <fpage>1153</fpage>–<lpage>1160</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201003-0491OC</pub-id>
<pub-id pub-id-type="pmid">20581168</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>D. F.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>King</surname><given-names>J. A.</given-names></name><name><surname>Elzarrad</surname><given-names>M. K.</given-names></name><name><surname>Yoder</surname><given-names>M. C.</given-names></name><name><surname>Stevens</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Lung microvascular endothelium is enriched with progenitor cells that exhibit vasculogenic capacity</article-title>. <source>Am. J. Physiol.-Lung Cell. Mol. Physiol.</source>
<volume>294</volume>, <fpage>L419</fpage>–<lpage>L430</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00314.2007</pub-id>
<pub-id pub-id-type="pmid">18065657</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archontogeorgis</surname><given-names>K.</given-names></name><name><surname>Steiropoulos</surname><given-names>P.</given-names></name><name><surname>Tzouvelekis</surname><given-names>A.</given-names></name><name><surname>Nena</surname><given-names>E.</given-names></name><name><surname>Bouros</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Lung cancer and interstitial lung diseases: a systematic review</article-title>. <source>Pulm. Med.</source>
<volume>2012</volume>, <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1155/2012/315918</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>M. J.</given-names></name><name><surname>Stang</surname><given-names>M. T.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>B.</given-names></name><name><surname>Zuckerbraun</surname><given-names>B. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Interferon Regulatory Factor 1 (IRF-1) induces p21 WAF1/CIP1 dependent cell cycle arrest and p21 WAF1/CIP1 independent modulation of survivin in cancer cells</article-title>. <source>Cancer Lett.</source>
<volume>319</volume>, <fpage>56</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2011.12.027</pub-id>
<pub-id pub-id-type="pmid">22200613</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asiedu</surname><given-names>M. K.</given-names></name><name><surname>Thomas</surname><given-names>C. F.</given-names></name><name><surname>Dong</surname><given-names>J.</given-names></name><name><surname>Schulte</surname><given-names>S. C.</given-names></name><name><surname>Khadka</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Pathways impacted by genomic alterations in pulmonary carcinoid tumors</article-title>. <source>Clin. Cancer Res.</source>
<volume>24</volume>, <fpage>1691</fpage>–<lpage>1704</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0252</pub-id>
<pub-id pub-id-type="pmid">29351916</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Xiong</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name></person-group> (<year>2019</year>). <article-title>Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma</article-title>. <source>Cancer Biomarkers</source>
<volume>24</volume>, <fpage>371</fpage>–<lpage>382</lpage>. <pub-id pub-id-type="doi">10.3233/CBM-181512</pub-id>
<pub-id pub-id-type="pmid">30883337</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballester</surname><given-names>R.</given-names></name><name><surname>Marchuk</surname><given-names>D.</given-names></name><name><surname>Boguski</surname><given-names>M.</given-names></name><name><surname>Saulino</surname><given-names>A.</given-names></name><name><surname>Letcher</surname><given-names>R.</given-names></name><name><surname>Wigler</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1990</year>). <article-title>The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins</article-title>. <source>Cell</source>
<volume>63</volume>, <fpage>851</fpage>–<lpage>859</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(90)90151-4</pub-id>
<pub-id pub-id-type="pmid">2121371</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretina</surname><given-names>J.</given-names></name><name><surname>Caponigro</surname><given-names>G.</given-names></name><name><surname>Stransky</surname><given-names>N.</given-names></name><name><surname>Venkatesan</surname><given-names>K.</given-names></name><name><surname>Margolin</surname><given-names>A. A.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>The cancer cell line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>. <source>Nature</source>
<volume>483</volume>, <fpage>603</fpage>–<lpage>607</lpage>. <pub-id pub-id-type="doi">10.1038/nature11003</pub-id>
<pub-id pub-id-type="pmid">22460905</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beard</surname><given-names>J. A.</given-names></name><name><surname>Tenga</surname><given-names>A.</given-names></name><name><surname>Hills</surname><given-names>J.</given-names></name><name><surname>Hoyer</surname><given-names>J. D.</given-names></name><name><surname>Cherian</surname><given-names>M. T.</given-names></name><name><surname>Wang</surname><given-names>Y. D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>The orphan nuclear receptor NR4A2 is part of a p53-microRNA-34 network</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>, <fpage>25108</fpage>. <pub-id pub-id-type="doi">10.1038/srep25108</pub-id>
<pub-id pub-id-type="pmid">27121375</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y.</given-names></name><name><surname>Hochberg</surname><given-names>Y.</given-names></name></person-group> (<year>1995</year>). <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J. R. Stat. Soc. Ser. B</source>
<volume>57</volume>, <fpage>289</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.2307/2346101</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bepler</surname><given-names>G.</given-names></name><name><surname>Kusmartseva</surname><given-names>I.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Gautam</surname><given-names>A.</given-names></name><name><surname>Cantor</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>RRM1 modulated <italic>in vitro</italic> and <italic>in vivo</italic> efficacy of gemcitabine and platinum in non–small-cell lung cancer</article-title>. <source>J. Clin. Oncol.</source>
<volume>24</volume>, <fpage>4731</fpage>–<lpage>4737</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2006.06.1101</pub-id>
<pub-id pub-id-type="pmid">16966686</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>A. H.</given-names></name><name><surname>Niki</surname><given-names>M.</given-names></name><name><surname>Morotti</surname><given-names>A.</given-names></name><name><surname>Taylor</surname><given-names>B. S.</given-names></name><name><surname>Socci</surname><given-names>N. D.</given-names></name><name><surname>Viale</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Identification of DOK genes as lung tumor suppressors</article-title>. <source>Nat. Genet.</source>
<volume>42</volume>, <fpage>216</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1038/ng.527</pub-id>
<pub-id pub-id-type="pmid">20139980</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertran-Alamillo</surname><given-names>J.</given-names></name><name><surname>Cattan</surname><given-names>V.</given-names></name><name><surname>Schoumacher</surname><given-names>M.</given-names></name><name><surname>Codony-Servat</surname><given-names>J.</given-names></name><name><surname>Giménez-Capitán</surname><given-names>A.</given-names></name><name><surname>Cantero</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy</article-title>. <source>Nat. Commun.</source>
<volume>10</volume>, <fpage>1812</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-09734-5</pub-id>
<pub-id pub-id-type="pmid">31000705</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchon</surname><given-names>F.</given-names></name><name><surname>Grivaux</surname><given-names>M.</given-names></name><name><surname>Asselain</surname><given-names>B.</given-names></name><name><surname>Lebas</surname><given-names>F. X.</given-names></name><name><surname>Orlando</surname><given-names>J. P.</given-names></name><name><surname>Piquet</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index</article-title>. <source>Lancet Oncol.</source>
<volume>7</volume>, <fpage>829</fpage>–<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(06)70868-3</pub-id>
<pub-id pub-id-type="pmid">17012045</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogaard</surname><given-names>H. J.</given-names></name><name><surname>Abe</surname><given-names>K.</given-names></name><name><surname>Noordegmaf</surname><given-names>A. V.</given-names></name><name><surname>Voelkel</surname><given-names>N. F.</given-names></name></person-group> (<year>2009</year>). <article-title>The right ventricle under pressure</article-title>. <source>Chest</source>
<volume>135</volume>, <fpage>794</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1378/chest.08-0492</pub-id>
<pub-id pub-id-type="pmid">19265089</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollag</surname><given-names>G.</given-names></name><name><surname>McCormick</surname><given-names>F.</given-names></name></person-group> (<year>1991</year>). <article-title>Differential regulation of rasGAP and neurofibromatosis gene product activities</article-title>. <source>Nature</source>
<volume>351</volume>, <fpage>576</fpage>–<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1038/351576a0</pub-id>
<pub-id pub-id-type="pmid">1904555</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouker</surname><given-names>K. B.</given-names></name><name><surname>Skaar</surname><given-names>T. C.</given-names></name><name><surname>Riggins</surname><given-names>R. B.</given-names></name><name><surname>Harburger</surname><given-names>D. S.</given-names></name><name><surname>Fernandez</surname><given-names>D. R.</given-names></name><name><surname>Zwart</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis</article-title>. <source>Carcinogenesis</source>
<volume>26</volume>, <fpage>1527</fpage>–<lpage>1535</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgi113</pub-id>
<pub-id pub-id-type="pmid">15878912</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowie</surname><given-names>M. L.</given-names></name><name><surname>Ibarra</surname><given-names>C.</given-names></name><name><surname>Seewalt</surname><given-names>V. L.</given-names></name></person-group> (<year>2008</year>). <article-title>IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: a model for early basal-type mammary carcinogenesis</article-title>. <source>Adv. In Exp. Med. Biol.</source>, <volume>617</volume>, <fpage>367</fpage>–<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-69080-3_35</pub-id>
<pub-id pub-id-type="pmid">18497060</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>M. M.</given-names></name><name><surname>Caporaso</surname><given-names>N. E.</given-names></name><name><surname>Page</surname><given-names>W. F.</given-names></name><name><surname>Hoover</surname><given-names>R. N.</given-names></name></person-group> (<year>1994</year>). <article-title>Genetic component of lung cancer: cohort study of twins</article-title>. <source>Lancet (London England)</source>
<volume>344</volume>, <fpage>440</fpage>–<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(94)91770-1</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Siegel</surname><given-names>R. L.</given-names></name><name><surname>Torre</surname><given-names>L. A.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA</article-title>. <source>Cancer J. Clin.</source>
<volume>68</volume>, <fpage>394</fpage>–<lpage>424</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brock</surname><given-names>M.</given-names></name><name><surname>Trenkmann</surname><given-names>M.</given-names></name><name><surname>Gay</surname><given-names>R. E.</given-names></name><name><surname>Michel</surname><given-names>B. A.</given-names></name><name><surname>Gay</surname><given-names>S.</given-names></name><name><surname>Fischler</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Interleukin-6 modulates the expression of the bone morphogenic protein receptor type ii through a novel STAT3-microRNA cluster 17/92 pathway</article-title>. <source>Circ. Res.</source>
<volume>104</volume>, <fpage>1184</fpage>–<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.197491</pub-id>
<pub-id pub-id-type="pmid">19390056</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>Z.-Y.</given-names></name><name><surname>Wang</surname><given-names>J.-Y.</given-names></name></person-group> (<year>2018</year>). <article-title>MiR-520b inhibited metastasis and proliferation of non-small cell lung cancer by targeting CHAF1A</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>22</volume>, <fpage>7742</fpage>–<lpage>7749</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_201811_16396.</pub-id>
<pub-id pub-id-type="pmid">30536318</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>E. R.</given-names></name><name><surname>Neil</surname><given-names>J. C.</given-names></name></person-group> (<year>2004</year>). <article-title>The Runx genes : lineage-specific oncogenes and tumor suppressors</article-title>. <source>Oncogene</source>
<volume>23</volume>, <fpage>4308</fpage>–<lpage>4314</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1207130</pub-id>
<pub-id pub-id-type="pmid">15156187</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Hou</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Prognostic value of BIRC5 in lung adenocarcinoma lacking EGFR, KRAS, and ALK mutations by integrated bioinformatics analysis</article-title>. <source>Dis. Markers</source>
<volume>2019</volume>, <fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1155/2019/5451290</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>L.</given-names></name><name><surname>Silva</surname><given-names>A.</given-names></name><name><surname>Andrade</surname><given-names>C.</given-names></name><name><surname>Barroso</surname><given-names>C.</given-names></name><name><surname>Farinha</surname><given-names>C.</given-names></name><name><surname>Fernandes</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>[ERCC1 and RRM1 genes in lung cancer]</article-title>. <source>Rev. Port. Pneumol.</source>
<volume>15</volume>, <fpage>683</fpage>–<lpage>696</lpage>. <pub-id pub-id-type="doi">10.1016/s0873-2159(15)30164-1</pub-id>
<pub-id pub-id-type="pmid">19552012</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaouat</surname><given-names>A.</given-names></name><name><surname>Coulet</surname><given-names>F.</given-names></name><name><surname>Favre</surname><given-names>C.</given-names></name><name><surname>Simonneau</surname><given-names>G.</given-names></name><name><surname>Weitzenblum</surname><given-names>E.</given-names></name><name><surname>Soubrier</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension</article-title>. <source>Thorax</source>
<volume>59</volume>, <fpage>446</fpage>–<lpage>448</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2003.11890</pub-id>
<pub-id pub-id-type="pmid">15115879</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Kljavin</surname><given-names>N. M.</given-names></name><name><surname>Haley</surname><given-names>B.</given-names></name><name><surname>Daemen</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma</article-title>. <source>Genes Cancer</source>
<volume>6</volume>, <fpage>106</fpage>. <pub-id pub-id-type="doi">10.18632/genesandcancer.53</pub-id>
<pub-id pub-id-type="pmid">26000094</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>C. H. Y.</given-names></name><name><surname>Hsu</surname><given-names>C. L.</given-names></name><name><surname>Chen</surname><given-names>K. P.</given-names></name><name><surname>Chong</surname><given-names>S. T.</given-names></name><name><surname>Wu</surname><given-names>C. H.</given-names></name><name><surname>Huang</surname><given-names>H. C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>MCM2-regulated functional networks in lung cancer by multi-dimensional proteomic approach</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>13302</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-13440-x</pub-id>
<pub-id pub-id-type="pmid">29038488</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chhina</surname><given-names>M. K.</given-names></name><name><surname>Nathan</surname><given-names>S. D.</given-names></name><name><surname>Emblom-Callahan</surname><given-names>M. C.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Shlobin</surname><given-names>O. A.</given-names></name><name><surname>Lemma</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Immunohistochemistry analysis for proliferation marker in IPF lung tissue</article-title>. <source>Chest</source>
<volume>138</volume>, <fpage>540A</fpage>. <pub-id pub-id-type="doi">10.1378/chest.9899</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J. H.</given-names></name><name><surname>Gelinas</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Etheridge</surname><given-names>A.</given-names></name><name><surname>Piper</surname><given-names>M. G.</given-names></name><name><surname>Batte</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes</article-title>. <source>BMC Med. Genomics</source>
<volume>4</volume>, <fpage>8</fpage>. <pub-id pub-id-type="doi">10.1186/1755-8794-4-8</pub-id>
<pub-id pub-id-type="pmid">21241464</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>E.-B.</given-names></name><name><surname>Yang</surname><given-names>A.-Y.</given-names></name><name><surname>Kim</surname><given-names>S. C.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Choi</surname><given-names>J. K.</given-names></name><name><surname>Choi</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair</article-title>. <source>Oncogene</source>
<volume>35</volume>, <fpage>4569</fpage>–<lpage>4579</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2016.3</pub-id>
<pub-id pub-id-type="pmid">26898760</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>B.</given-names></name><name><surname>LaLonde</surname><given-names>A.</given-names></name><name><surname>Que</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions</article-title>. <source>Hum. Pathol.</source>
<volume>57</volume>, <fpage>126</fpage>–<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2016.07.013</pub-id>
<pub-id pub-id-type="pmid">27476776</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christmann</surname><given-names>R. B.</given-names></name><name><surname>Wooten</surname><given-names>A.</given-names></name><name><surname>Sampaio-Barros</surname><given-names>P.</given-names></name><name><surname>Borges</surname><given-names>C. L.</given-names></name><name><surname>Carlos</surname><given-names>C. R.</given-names></name><name><surname>Kairalla</surname><given-names>R. A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>miR-155 in the progression of lung fibrosis in systemic sclerosis</article-title>. <source>Arthritis Res. Ther.</source>
<volume>18</volume>, <fpage>155</fpage>. <pub-id pub-id-type="doi">10.1186/S13075-016-1054-6</pub-id>
<pub-id pub-id-type="pmid">27377409</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collisson</surname><given-names>E. A.</given-names></name><name><surname>Campbell</surname><given-names>J. D.</given-names></name><name><surname>Brooks</surname><given-names>A. N.</given-names></name><name><surname>Berger</surname><given-names>A. H.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name><name><surname>Chmielecki</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network</article-title>. <source>Nature</source>
<volume>511</volume>, <fpage>543</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1038/nature13385</pub-id>
<pub-id pub-id-type="pmid">25079552</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>R.</given-names></name><name><surname>Bruce</surname><given-names>M.</given-names></name><name><surname>Wootton</surname><given-names>A.</given-names></name><name><surname>Hands</surname><given-names>D.</given-names></name><name><surname>Daly</surname><given-names>L.</given-names></name></person-group> (<year>2003</year>). <article-title>Managing design in the extended enterprise</article-title>. <source>Build. Res. Inf.</source>
<volume>22</volume>, <fpage>367</fpage>–<lpage>378</lpage>. <pub-id pub-id-type="doi">10.1080/0961321032000107555</pub-id>
</mixed-citation>
    </ref>
    <ref id="B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>W. A.</given-names></name><name><surname>Kohonen-Corish</surname><given-names>M. R. J.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name><name><surname>Kwun</surname><given-names>S. Y.</given-names></name><name><surname>McCaughan</surname><given-names>B.</given-names></name><name><surname>Kennedy</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions</article-title>. <source>Histopathology</source>
<volume>52</volume>, <fpage>613</fpage>–<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2559.2008.02999.x</pub-id>
<pub-id pub-id-type="pmid">18370958</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coultas</surname><given-names>D. B.</given-names></name><name><surname>Zumwalt</surname><given-names>R. E.</given-names></name><name><surname>Black</surname><given-names>W. C.</given-names></name><name><surname>Sobonya</surname><given-names>R. E.</given-names></name></person-group> (<year>1994</year>). <article-title>The epidemiology of interstitial lung diseases</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>150</volume>, <fpage>967</fpage>–<lpage>972</lpage>. <pub-id pub-id-type="doi">10.1164/ajrccm.150.4.7921471</pub-id>
<pub-id pub-id-type="pmid">7921471</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courboulin</surname><given-names>A.</given-names></name><name><surname>Paulin</surname><given-names>R.</given-names></name><name><surname>Giguère</surname><given-names>N. J.</given-names></name><name><surname>Saksouk</surname><given-names>N.</given-names></name><name><surname>Perreault</surname><given-names>T.</given-names></name><name><surname>Meloche</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Role for miR-204 in human pulmonary arterial hypertension</article-title>. <source>J. Exp. Med.</source>
<volume>208</volume>, <fpage>535</fpage>–<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20101812</pub-id>
<pub-id pub-id-type="pmid">21321078</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S. K.</given-names></name><name><surname>Menezes</surname><given-names>M. E.</given-names></name><name><surname>Bhatia</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>X.-Y.</given-names></name><name><surname>Emdad</surname><given-names>L.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Gene therapies for cancer: strategies, challenges and successes</article-title>. <source>J. Cell. Physiol.</source>
<volume>230</volume>, <fpage>259</fpage>–<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.24791</pub-id>
<pub-id pub-id-type="pmid">25196387</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dela Cruz</surname><given-names>C. S.</given-names></name><name><surname>Tanoue</surname><given-names>L. T.</given-names></name><name><surname>Matthay</surname><given-names>R. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Lung cancer: epidemiology, etiology, and prevention</article-title>. <source>Clin. Chest Med.</source>
<volume>32</volume>, <fpage>605</fpage>–<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccm.2011.09.001</pub-id>
<pub-id pub-id-type="pmid">22054876</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeNicola</surname><given-names>G. M.</given-names></name><name><surname>Chen</surname><given-names>P. H.</given-names></name><name><surname>Mullarky</surname><given-names>E.</given-names></name><name><surname>Sudderth</surname><given-names>J. A.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>NRF2 regulates serine biosynthesis in non-small cell lung cancer</article-title>. <source>Nat. Genet.</source>
<volume>47</volume>, <fpage>1475</fpage>–<lpage>1481</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3421</pub-id>
<pub-id pub-id-type="pmid">26482881</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>G.</given-names></name><name><surname>Sherman</surname><given-names>B. T.</given-names></name><name><surname>Hosack</surname><given-names>D. A.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Lane</surname><given-names>H. C.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>DAVID: Database for annotation, visualization, and integrated discovery</article-title>. <source>Genome Biol.</source>
<volume>4</volume>
<fpage>P3</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2003-4-9-r60</pub-id>
<pub-id pub-id-type="pmid">12734009</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingemans</surname><given-names>A. C.</given-names></name><name><surname>van Ark-Otte</surname><given-names>J.</given-names></name><name><surname>Span</surname><given-names>S.</given-names></name><name><surname>Scagliotti</surname><given-names>G. V.</given-names></name><name><surname>van der Valk</surname><given-names>P.</given-names></name><name><surname>Postmus</surname><given-names>P. E.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer</article-title>. <source>Lung Cancer</source>
<volume>32</volume>, <fpage>117</fpage>–<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-5002(00)00224-5</pub-id>
<pub-id pub-id-type="pmid">11325482</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dornan</surname><given-names>D.</given-names></name><name><surname>Eckert</surname><given-names>M.</given-names></name><name><surname>Wallace</surname><given-names>M.</given-names></name><name><surname>Shimizu</surname><given-names>H.</given-names></name><name><surname>Ramsay</surname><given-names>E.</given-names></name><name><surname>Hupp</surname><given-names>T. R.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Interferon Regulatory Factor 1 Binding to p300 Stimulates DNA-Dependent Acetylation of p53
</article-title>. <source>Mol. Cell. Biol.</source>
<volume>24</volume>, <fpage>10083</fpage>–<lpage>10098</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.24.22.10083-10098.2004</pub-id>
<pub-id pub-id-type="pmid">15509808</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>E. O.</given-names></name><name><surname>Carneiro-Lobo</surname><given-names>T. C.</given-names></name><name><surname>Aoki</surname><given-names>M. N.</given-names></name><name><surname>Levantini</surname><given-names>E.</given-names></name><name><surname>Bassères</surname><given-names>D. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Aurora kinase targeting in lung cancer reduces KRAS-induced transformation</article-title>. <source>Mol. Cancer</source>
<volume>15</volume>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-016-0494-6</pub-id>
<pub-id pub-id-type="pmid">26842935</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Chemaly</surname><given-names>S.</given-names></name><name><surname>Cheung</surname><given-names>F.</given-names></name><name><surname>Kotliarov</surname><given-names>Y.</given-names></name><name><surname>O’Brien</surname><given-names>K. J.</given-names></name><name><surname>Gahl</surname><given-names>W. A.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>a). <article-title>The immunome in two inherited forms of pulmonary fibrosis</article-title>. <source>Front. Immunol.</source>
<volume>9</volume>, <fpage>76</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00076</pub-id>
<pub-id pub-id-type="pmid">29445374</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Chemaly</surname><given-names>S.</given-names></name><name><surname>Cheung</surname><given-names>F.</given-names></name><name><surname>Kotliarov</surname><given-names>Y.</given-names></name><name><surname>O’Brien</surname><given-names>K. J.</given-names></name><name><surname>Gahl</surname><given-names>W. A.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>b). <article-title>The immunome in two inherited forms of pulmonary fibrosis</article-title>. <source>Front. Immunol.</source>
<volume>9</volume>, <fpage>76</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00076</pub-id>
<pub-id pub-id-type="pmid">29445374</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ergün</surname><given-names>S.</given-names></name><name><surname>Tilki</surname><given-names>D.</given-names></name><name><surname>Klein</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>Vascular wall as a reservoir for different types of stem and progenitor cells</article-title>. <source>Antioxidants Redox Signal.</source>
<volume>15</volume>, <fpage>981</fpage>–<lpage>995</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2010.3507</pub-id>
</mixed-citation>
    </ref>
    <ref id="B49">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eswaran</surname><given-names>J.</given-names></name><name><surname>Horvath</surname><given-names>A.</given-names></name><name><surname>Godbole</surname><given-names>S.</given-names></name><name><surname>Reddy</surname><given-names>S. D.</given-names></name><name><surname>Mudvari</surname><given-names>P.</given-names></name><name><surname>Ohshiro</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>RNA sequencing of cancer reveals novel splicing alterations</article-title>. <source>Sci. Rep.</source>
<volume>3</volume>, <fpage>1689</fpage>. <pub-id pub-id-type="doi">10.1038/srep01689</pub-id>
<pub-id pub-id-type="pmid">23604310</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eymin</surname><given-names>B.</given-names></name><name><surname>Gazzeri</surname><given-names>S.</given-names></name><name><surname>Brambilla</surname><given-names>C.</given-names></name><name><surname>Brambilla</surname><given-names>E.</given-names></name></person-group> (<year>2001</year>). <article-title>Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma</article-title>. <source>Oncogene</source>
<volume>20</volume>, <fpage>1678</fpage>–<lpage>1687</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1204242</pub-id>
<pub-id pub-id-type="pmid">11313916</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falleni</surname><given-names>M.</given-names></name><name><surname>Pellegrini</surname><given-names>C.</given-names></name><name><surname>Marchetti</surname><given-names>A.</given-names></name><name><surname>Oprandi</surname><given-names>B.</given-names></name><name><surname>Buttitta</surname><given-names>F.</given-names></name><name><surname>Barassi</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Survivin gene expression in early-stage non-small cell lung cancer</article-title>. <source>J. Pathol.</source>
<volume>200</volume>, <fpage>620</fpage>–<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1002/path.1388</pub-id>
<pub-id pub-id-type="pmid">12898598</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>RACK1 promotes lung cancer cell growth via an MCM7/RACK1/Akt signaling complex</article-title>. <source>Oncotarget</source>
<volume>8</volume>, <fpage>40501</fpage>–<lpage>40513</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.17120</pub-id>
<pub-id pub-id-type="pmid">28465488</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Fenton</surname><given-names>M. D.</given-names></name><name><surname>Weyrich</surname><given-names>M. S.</given-names></name><name><surname>Durbin</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Bang</surname><given-names>H.</given-names></name><name><surname>Melnikow</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <source>Prostate-Specific Antigen-Based Screening for Prostate Cancer</source> ((US): Agency for Healthcare Research and Quality). Available at: <uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22171385">http://www.ncbi.nlm.nih.gov/pubmed/22171385</uri> [Accessed <date-in-citation>October 25, 2018</date-in-citation>].</mixed-citation>
    </ref>
    <ref id="B54">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ficklin</surname><given-names>S. P.</given-names></name><name><surname>Dunwoodie</surname><given-names>L. J.</given-names></name><name><surname>Poehlman</surname><given-names>W. L.</given-names></name><name><surname>Watson</surname><given-names>C.</given-names></name><name><surname>Roche</surname><given-names>K. E.</given-names></name><name><surname>Feltus</surname><given-names>F. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Discovering condition-specific gene co-expression patterns using gaussian mixture models: a cancer case study</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-09094-4</pub-id>
<pub-id pub-id-type="pmid">28127051</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fragale</surname><given-names>A.</given-names></name><name><surname>Gabriele</surname><given-names>L.</given-names></name><name><surname>Stellacci</surname><given-names>E.</given-names></name><name><surname>Borghi</surname><given-names>P.</given-names></name><name><surname>Perrotti</surname><given-names>E.</given-names></name><name><surname>Ilari</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>IFN Regulatory Factor-1 Negatively Regulates CD4+CD25+ Regulatory T cell differentiation by repressing Foxp3 expression</article-title>. <source>J. Immunol.</source>
<volume>181</volume>, <fpage>1673</fpage>–<lpage>1682</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.3.1673</pub-id>
</mixed-citation>
    </ref>
    <ref id="B56">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gahring</surname><given-names>L. C.</given-names></name><name><surname>Myers</surname><given-names>E. J.</given-names></name><name><surname>Dunn</surname><given-names>D. M.</given-names></name><name><surname>Weiss</surname><given-names>R. B.</given-names></name><name><surname>Rogers</surname><given-names>S. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Lung epithelial response to cigarette smoke and modulation by the nicotinic alpha 7 receptor</article-title>. <source>PloS ONE</source>
<volume>12</volume>, <fpage>e0187773</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0187773</pub-id>
<pub-id pub-id-type="pmid">29117258</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells</article-title>. <source>FEBS J.</source>
<volume>285</volume>, <fpage>4229</fpage>–<lpage>4245</lpage>. <pub-id pub-id-type="doi">10.1111/febs.14665</pub-id>
<pub-id pub-id-type="pmid">30251328</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautier</surname><given-names>L.</given-names></name><name><surname>Cope</surname><given-names>L.</given-names></name><name><surname>Bolstad</surname><given-names>B. M.</given-names></name><name><surname>Irizarry</surname><given-names>R. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Affy - Analysis of affymetrix genechip data at the probe level</article-title>. <source>Bioinformatics</source>
<volume>20</volume>, <fpage>307</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btg405</pub-id>
<pub-id pub-id-type="pmid">14960456</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giopanou</surname><given-names>I.</given-names></name><name><surname>Papaleonidopoulos</surname><given-names>V.</given-names></name><name><surname>Lilis</surname><given-names>I.</given-names></name><name><surname>Kanellakis</surname><given-names>N.</given-names></name><name><surname>Agalioti</surname><given-names>T.</given-names></name><name><surname>Stathopoulos</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Tumor cell-derived osteopontin promotes lung metastasis via both cell-autonomous and paracrine pathways. in 11.1
</article-title>. <source>Lung Cancer European Resp. Soc. </source><volume>48</volume>, <fpage>OA1525</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.congress-2016.oa1525</pub-id>
</mixed-citation>
    </ref>
    <ref id="B60">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girerd</surname><given-names>B.</given-names></name><name><surname>Montani</surname><given-names>D.</given-names></name><name><surname>Coulet</surname><given-names>F.</given-names></name><name><surname>Sztrymf</surname><given-names>B.</given-names></name><name><surname>Yaici</surname><given-names>A.</given-names></name><name><surname>Jaïs</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>181</volume>, <fpage>851</fpage>–<lpage>861</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200908-1284OC</pub-id>
<pub-id pub-id-type="pmid">20056902</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Arroyo</surname><given-names>J.</given-names></name><name><surname>Saleem</surname><given-names>S. J.</given-names></name><name><surname>Mizuno</surname><given-names>S.</given-names></name><name><surname>Syed</surname><given-names>A. A.</given-names></name><name><surname>Bogaard</surname><given-names>H. J.</given-names></name><name><surname>Abbate</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects</article-title>. <source>Am. J. Physiol. - Lung Cell. Mol. Physiol. </source><volume>10</volume>, <fpage>302</fpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00362.2011</pub-id>
</mixed-citation>
    </ref>
    <ref id="B62">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordenin</surname><given-names>D. A.</given-names></name><name><surname>Kunkel</surname><given-names>T. A.</given-names></name><name><surname>Resnick</surname><given-names>M. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Repeat expansion - All in a flap</article-title>? <source>Nat. Genet.</source>
<volume>16</volume>, <fpage>116</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1038/ng0697-116</pub-id>
<pub-id pub-id-type="pmid">9171819</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gridelli</surname><given-names>C.</given-names></name><name><surname>Rossi</surname><given-names>A.</given-names></name><name><surname>Carbone</surname><given-names>D. P.</given-names></name><name><surname>Guarize</surname><given-names>J.</given-names></name><name><surname>Karachaliou</surname><given-names>N.</given-names></name><name><surname>Mok</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Non-small-cell lung cancer</article-title>. <source>Nat. Rev. Dis. Prim.</source>
<volume>1</volume>, <fpage>15009</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2015.9</pub-id>
<pub-id pub-id-type="pmid">27188576</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griese</surname><given-names>M.</given-names></name><name><surname>Irnstetter</surname><given-names>A.</given-names></name><name><surname>Hengst</surname><given-names>M.</given-names></name><name><surname>Burmester</surname><given-names>H.</given-names></name><name><surname>Nagel</surname><given-names>F.</given-names></name><name><surname>Ripper</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Categorizing diffuse parenchymal lung disease in children rare pulmonary diseases</article-title>. <source>Orphanet J. Rare Dis.</source>
<volume>10</volume>, <fpage>122</fpage>. <pub-id pub-id-type="doi">10.1186/s13023-015-0339-1</pub-id>
<pub-id pub-id-type="pmid">26408013</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guignabert</surname><given-names>C.</given-names></name><name><surname>Dorfmuller</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Pathology and pathobiology of pulmonary hypertension</article-title>. <source>Semin. Respir. Crit. Care Med.</source>
<volume>34</volume>, <fpage>551</fpage>–<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1055/s-0033-1356496</pub-id>
<pub-id pub-id-type="pmid">24037624</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guignabert</surname><given-names>C.</given-names></name><name><surname>Tu</surname><given-names>L.</given-names></name><name><surname>Le Hiress</surname><given-names>M.</given-names></name><name><surname>Ricard</surname><given-names>N.</given-names></name><name><surname>Sattler</surname><given-names>C.</given-names></name><name><surname>Seferian</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Pathogenesis of pulmonary arterial hypertension: lessons from cancer</article-title>. <source>Eur. Respir. Rev.</source>
<volume>22</volume>, <fpage>543</fpage>–<lpage>551</lpage>. <pub-id pub-id-type="doi">10.1183/09059180.00007513</pub-id>
<pub-id pub-id-type="pmid">24293470</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyorffy</surname><given-names>B.</given-names></name><name><surname>Surowiak</surname><given-names>P.</given-names></name><name><surname>Budczies</surname><given-names>J.</given-names></name><name><surname>Lánczky</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer</article-title>. <source>PloS ONE</source>
<volume>8</volume>, <fpage>e82241</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0082241</pub-id>
<pub-id pub-id-type="pmid">24367507</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammerman</surname><given-names>P. S.</given-names></name><name><surname>Voet</surname><given-names>D.</given-names></name><name><surname>Lawrence</surname><given-names>M. S.</given-names></name><name><surname>Voet</surname><given-names>D.</given-names></name><name><surname>Jing</surname><given-names>R.</given-names></name><name><surname>Cibulskis</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Comprehensive genomic characterization of squamous cell lung cancers</article-title>. <source>Nature</source>
<volume>489</volume>, <fpage>519</fpage>–<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1038/nature11404</pub-id>
<pub-id pub-id-type="pmid">22960745</pub-id></mixed-citation>
    </ref>
    <ref id="B69">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>
<volume>144</volume>, <fpage>646</fpage>–<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
<pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation>
    </ref>
    <ref id="B70">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2017</year>a). <article-title>FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer</article-title>. <source>Mol. Oncol.</source>
<volume>11</volume>, <fpage>640</fpage>–<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1002/1878-0261.12058</pub-id>
<pub-id pub-id-type="pmid">28371273</pub-id></mixed-citation>
    </ref>
    <ref id="B71">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Z. Y.</given-names></name><name><surname>Wu</surname><given-names>S. G.</given-names></name><name><surname>Peng</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>b). <article-title>Up-regulation of RFC3 promotes triple negative breast cancer metastasis and is associated with poor prognosis via EMT</article-title>. <source>Transl. Oncol.</source>
<volume>10</volume>, <fpage>1</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.tranon.2016.10.004</pub-id>
<pub-id pub-id-type="pmid">27888707</pub-id></mixed-citation>
    </ref>
    <ref id="B72">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henao</surname><given-names>J.</given-names></name><name><surname>Lopez-Kleine</surname><given-names>L.</given-names></name><name><surname>Pinzon-Velasco</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <source>coexnet: coexnet: An R package to build CO-EXpression NETworks from Microarray Data. </source>R package version <fpage>1</fpage><fpage>4</fpage>.0</mixed-citation>
    </ref>
    <ref id="B73">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>H.</given-names></name><name><surname>Maeda</surname><given-names>H.</given-names></name><name><surname>Yamaguchi</surname><given-names>T.</given-names></name><name><surname>Yokota</surname><given-names>S.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Sakoda</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Survivin expression in lung cancer: association with smoking, histological types and pathological stages</article-title>. <source>Oncol. Lett.</source>
<volume>10</volume>, <fpage>1456</fpage>–<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2015.3374</pub-id>
<pub-id pub-id-type="pmid">26622690</pub-id></mixed-citation>
    </ref>
    <ref id="B74">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeper</surname><given-names>M. M.</given-names></name><name><surname>Barst</surname><given-names>R. J.</given-names></name><name><surname>Bourge</surname><given-names>R. C.</given-names></name><name><surname>Feldman</surname><given-names>J.</given-names></name><name><surname>Frost</surname><given-names>A. E.</given-names></name><name><surname>Galié</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study</article-title>. <source>Circulation</source>
<volume>127</volume>, <fpage>1128</fpage>–<lpage>1138</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.000765</pub-id>
<pub-id pub-id-type="pmid">23403476</pub-id></mixed-citation>
    </ref>
    <ref id="B75">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>G. X.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter</article-title>. <source>PloS One</source>
<volume>12</volume>, <fpage>e0174515</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0174515</pub-id>
<pub-id pub-id-type="pmid">28355294</pub-id></mixed-citation>
    </ref>
    <ref id="B76">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Identification of potential diagnostic and prognostic biomarkers in non-small cell lung cancer based on microarray data</article-title>. <source>Oncol. Lett.</source>
<volume>15</volume>, <fpage>6436</fpage>–<lpage>6442</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.8153</pub-id>
<pub-id pub-id-type="pmid">29731852</pub-id></mixed-citation>
    </ref>
    <ref id="B77">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Transcription factor YY1 modulates lung cancer progression by activating lncRNA-PVT1
</article-title>. <source>DNA Cell Biol.</source>
<volume>36</volume>, <fpage>947</fpage>–<lpage>958</lpage>. <pub-id pub-id-type="doi">10.1089/dna.2017.3857</pub-id>
<pub-id pub-id-type="pmid">28972861</pub-id></mixed-citation>
    </ref>
    <ref id="B78">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>W.</given-names></name><name><surname>Von Heydebreck</surname><given-names>A.</given-names></name><name><surname>Sültmann</surname><given-names>H.</given-names></name><name><surname>Poustka</surname><given-names>A.</given-names></name><name><surname>Vingron</surname><given-names>M.</given-names></name></person-group> (<year>2002</year>). <article-title>Variance stabilization applied to microarray data calibration and to the quantification of differential expression</article-title>. <source>Bioinformatics</source>
<volume>18</volume>, <fpage>S96</fpage>–<fpage>S104</fpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/18.suppl_1.S96</pub-id>
<pub-id pub-id-type="pmid">12169536</pub-id></mixed-citation>
    </ref>
    <ref id="B79">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>IARC</collab><name><surname>Boyle</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>World cancer report 2018
</article-title>. <source>Cancer Control</source>
<volume>199</volume>, <fpage>512</fpage>. <pub-id pub-id-type="doi">10.1016/j.cma.2010.02.010</pub-id>
</mixed-citation>
    </ref>
    <ref id="B80">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iguchi</surname><given-names>H.</given-names></name><name><surname>Hara</surname><given-names>N.</given-names></name><name><surname>Hayashi</surname><given-names>I.</given-names></name><name><surname>Ohta</surname><given-names>M.</given-names></name><name><surname>Bloom</surname><given-names>S. R.</given-names></name><name><surname>Chrétien</surname><given-names>M.</given-names></name></person-group> (<year>1989</year>). <article-title>Elevation of a novel pituitary protein (7B2) in the plasma in small cell carcinoma of the lung</article-title>. <source>Eur. J. Cancer Clin. Oncol.</source>
<volume>25</volume>, <fpage>1225</fpage>–<lpage>1232</lpage>. <pub-id pub-id-type="doi">10.1016/0277-5379(89)90419-7</pub-id>
<pub-id pub-id-type="pmid">2548871</pub-id></mixed-citation>
    </ref>
    <ref id="B81">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivliev</surname><given-names>A. E.</given-names></name><name><surname>Hoen</surname><given-names>P. A.</given-names></name><name><surname>Borisevich</surname><given-names>D.</given-names></name><name><surname>Nikolsky</surname><given-names>Y.</given-names></name><name><surname>Sergeeva</surname><given-names>M. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Drug repositioning through systematic mining of gene coexpression networks in cancer</article-title>. <source>PloS One</source>
<volume>11</volume>, <fpage>e0165059</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0165059</pub-id>
<pub-id pub-id-type="pmid">27824868</pub-id></mixed-citation>
    </ref>
    <ref id="B82">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janky</surname><given-names>R.</given-names></name><name><surname>Verfaillie</surname><given-names>A.</given-names></name><name><surname>Imrichová</surname><given-names>H.</given-names></name><name><surname>de Sande</surname><given-names>B.</given-names></name><name><surname>Standaert</surname><given-names>L.</given-names></name><name><surname>Christiaens</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>iRegulon: from a gene list to a gene regulatory network using large motif and track collections</article-title>. <source>PloS Comput. Biol.</source>
<volume>10</volume>, <fpage>e1003731</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1003731</pub-id>
<pub-id pub-id-type="pmid">25058159</pub-id></mixed-citation>
    </ref>
    <ref id="B83">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L. H.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>J. H.</given-names></name></person-group> (<year>2018</year>). <article-title>MiR-30a: a novel biomarker and potential therapeutic target for cancer</article-title>. <source>J. Oncol.</source>
<volume>2018</volume>, <fpage>1</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1155/2018/5167829</pub-id>
</mixed-citation>
    </ref>
    <ref id="B84">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H. I.</given-names></name><name><surname>Park</surname><given-names>J. S.</given-names></name><name><surname>Lee</surname><given-names>M.-Y.</given-names></name><name><surname>Park</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Park</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease</article-title>. <source>Med. (Baltimore).</source>
<volume>97</volume>, <fpage>1</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000010071</pub-id>
</mixed-citation>
    </ref>
    <ref id="B85">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamel</surname><given-names>H. F. M.</given-names></name><name><surname>Al-Amodi</surname><given-names>H. S. A. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Exploitation of Gene Expression and cancer biomarkers in paving the path to era of personalized medicine</article-title>. <source>Genomics Proteomics Bioinforma.</source>
<volume>15</volume>, <fpage>220</fpage>–<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.gpb.2016.11.005</pub-id>
</mixed-citation>
    </ref>
    <ref id="B86">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Cruz</surname><given-names>W.</given-names></name><name><surname>Ujiie</surname><given-names>H.</given-names></name><name><surname>Fujino</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Personalized siRNA-nanoparticle systemic therapy using metastatic lymph node specimens obtained with EBUS-TBNA in lung cancer</article-title>. <source>Mol. Cancer Res.</source>
<volume>16</volume>, <fpage>47</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-16-0341</pub-id>
<pub-id pub-id-type="pmid">28993508</pub-id></mixed-citation>
    </ref>
    <ref id="B87">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufhold</surname><given-names>S.</given-names></name><name><surname>Garbán</surname><given-names>H.</given-names></name><name><surname>Bonavida</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication</article-title>. <source>J. Exp. Clin. Cancer Res.</source>
<volume>35</volume>, <fpage>1</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1186/s13046-016-0359-2</pub-id>
<pub-id pub-id-type="pmid">26728266</pub-id></mixed-citation>
    </ref>
    <ref id="B88">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H. P.</given-names></name><name><surname>Kaminski</surname><given-names>N.</given-names></name><name><surname>Feghali-Bostwick</surname><given-names>C. A.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Oury</surname><given-names>T. D.</given-names></name><name><surname>Choi</surname><given-names>A. M. K.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis</article-title>. <source>J. Exp. Med.</source>
<volume>203</volume>, <fpage>2895</fpage>–<lpage>2906</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20061536</pub-id>
<pub-id pub-id-type="pmid">17178917</pub-id></mixed-citation>
    </ref>
    <ref id="B89">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogan</surname><given-names>E. A.</given-names></name><name><surname>Tyong</surname><given-names>F. V.</given-names></name><name><surname>Demura</surname><given-names>S. A.</given-names></name></person-group> (<year>2010</year>). <article-title>The mechanism of lung tissue remodeling in the progression of idiopathic pulmonary fibrosis</article-title>. <source>Arkh. Patol.</source>
<volume>72</volume>, <fpage>30</fpage>–<lpage>36</lpage>. Available at: <uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/21086635">http://www.ncbi.nlm.nih.gov/pubmed/21086635</uri> [Accessed <date-in-citation>December 9, 2018</date-in-citation>].</mixed-citation>
    </ref>
    <ref id="B90">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konishi</surname><given-names>K.</given-names></name><name><surname>Gibson</surname><given-names>K. F.</given-names></name><name><surname>Lindell</surname><given-names>K. O.</given-names></name><name><surname>Richards</surname><given-names>T. J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Dhir</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>180</volume>, <fpage>167</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200810-1596OC</pub-id>
<pub-id pub-id-type="pmid">19363140</pub-id></mixed-citation>
    </ref>
    <ref id="B91">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koper</surname><given-names>A.</given-names></name><name><surname>Zeef</surname><given-names>L. A. H.</given-names></name><name><surname>Joseph</surname><given-names>L.</given-names></name><name><surname>Kerr</surname><given-names>K.</given-names></name><name><surname>Gosney</surname><given-names>J.</given-names></name><name><surname>Lindsay</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Whole transcriptome analysis of pre-invasive and invasive early squamous lung carcinoma in archival laser microdissected samples</article-title>. <source>Respir. Res.</source>
<volume>18</volume>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-016-0496-3</pub-id>
<pub-id pub-id-type="pmid">28073359</pub-id></mixed-citation>
    </ref>
    <ref id="B92">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korošec</surname><given-names>B.</given-names></name><name><surname>Glavač</surname><given-names>D.</given-names></name><name><surname>Rott</surname><given-names>T.</given-names></name><name><surname>Ravnik-Glavač</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Alterations in the ATP2A2 gene in correlation with colon and lung cancer</article-title>. <source>Cancer Genet. Cytogenet.</source>
<volume>171</volume>, <fpage>105</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.cancergencyto.2006.06.016</pub-id>
<pub-id pub-id-type="pmid">17116488</pub-id></mixed-citation>
    </ref>
    <ref id="B93">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kropski</surname><given-names>J. A.</given-names></name><name><surname>Blackwell</surname><given-names>T. S.</given-names></name><name><surname>Loyd</surname><given-names>J. E.</given-names></name></person-group> (<year>2015</year>). <article-title>The genetic basis of idiopathic pulmonary fibrosis</article-title>. <source>Eur. Respir. J.</source>
<volume>45</volume>, <fpage>1717</fpage>–<lpage>1727</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00163814</pub-id>
<pub-id pub-id-type="pmid">25837031</pub-id></mixed-citation>
    </ref>
    <ref id="B94">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kweh</surname><given-names>F.</given-names></name><name><surname>Min</surname><given-names>Z.</given-names></name><name><surname>Kurenova</surname><given-names>E.</given-names></name><name><surname>Wallace</surname><given-names>M.</given-names></name><name><surname>Golubovskaya</surname><given-names>V.</given-names></name><name><surname>Cance</surname><given-names>W. G.</given-names></name></person-group> (<year>2009</year>). <article-title>Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase</article-title>. <source>Mol. Carcinog.</source>
<volume>48</volume>, <fpage>1005</fpage>–<lpage>1017</lpage>. <pub-id pub-id-type="doi">10.1002/mc.20552</pub-id>
<pub-id pub-id-type="pmid">19479903</pub-id></mixed-citation>
    </ref>
    <ref id="B95">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lajoie</surname><given-names>A. C.</given-names></name><name><surname>Lauzière</surname><given-names>G.</given-names></name><name><surname>Lega</surname><given-names>J. C.</given-names></name><name><surname>Lacasse</surname><given-names>Y.</given-names></name><name><surname>Martin</surname><given-names>S.</given-names></name><name><surname>Simard</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis</article-title>. <source>Lancet Respir. Med.</source>
<volume>4</volume>, <fpage>291</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(16)00027-8</pub-id>
<pub-id pub-id-type="pmid">26935844</pub-id></mixed-citation>
    </ref>
    <ref id="B96">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landi</surname><given-names>M. T.</given-names></name><name><surname>Dracheva</surname><given-names>T.</given-names></name><name><surname>Rotunno</surname><given-names>M.</given-names></name><name><surname>Figueroa</surname><given-names>J. D.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Dasgupta</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival</article-title>. <source>PloS ONE</source>
<volume>3</volume>, <fpage>e1651</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0001651</pub-id>
<pub-id pub-id-type="pmid">18297132</pub-id></mixed-citation>
    </ref>
    <ref id="B97">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>K. B.</given-names></name><name><surname>Machado</surname><given-names>R. D.</given-names></name><name><surname>Pauciulo</surname><given-names>M. W.</given-names></name><name><surname>Thomson</surname><given-names>J. R.</given-names></name><name><surname>Phillips</surname><given-names>J. A.</given-names></name><name><surname>Loyd</surname><given-names>J. E.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension</article-title>. <source>Nat. Genet.</source>
<volume>26</volume>, <fpage>81</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/79226</pub-id>
<pub-id pub-id-type="pmid">10973254</pub-id></mixed-citation>
    </ref>
    <ref id="B98">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>J. E.</given-names></name><name><surname>Nathan</surname><given-names>V.</given-names></name><name><surname>Osborne</surname><given-names>J. K.</given-names></name><name><surname>Farrow</surname><given-names>R. K.</given-names></name><name><surname>Deb</surname><given-names>D.</given-names></name><name><surname>Sullivan</surname><given-names>J. P.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>ZEB1 drives epithelial-to-mesenchymal transition in lung cancer</article-title>. <source>J. Clin. Invest.</source>
<volume>126</volume>, <fpage>3219</fpage>–<lpage>3235</lpage>. <pub-id pub-id-type="doi">10.1172/JCI76725</pub-id>
<pub-id pub-id-type="pmid">27500490</pub-id></mixed-citation>
    </ref>
    <ref id="B99">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Jeune</surname><given-names>I.</given-names></name><name><surname>Gribbin</surname><given-names>J.</given-names></name><name><surname>West</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name><name><surname>Cullinan</surname><given-names>P.</given-names></name><name><surname>Hubbard</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK</article-title>. <source>Respir. Med.</source>
<volume>101</volume>, <fpage>2534</fpage>–<lpage>2540</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2007.07.012</pub-id>
<pub-id pub-id-type="pmid">17870458</pub-id></mixed-citation>
    </ref>
    <ref id="B100">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>L. G.</given-names></name><name><surname>López</surname><given-names>C.</given-names></name><name><surname>López-Kleine</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Construction and comparison of gene co-expression networks shows complex plant immune responses</article-title>. <source>PeerJ</source>
<volume>2</volume>, <fpage>e610</fpage>. <pub-id pub-id-type="doi">10.7717/peerj.610</pub-id>
<pub-id pub-id-type="pmid">25320678</pub-id></mixed-citation>
    </ref>
    <ref id="B101">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Shroyer</surname><given-names>K. R.</given-names></name><name><surname>Markham</surname><given-names>N. E.</given-names></name><name><surname>Cool</surname><given-names>C. D.</given-names></name><name><surname>Voelkel</surname><given-names>N. F.</given-names></name><name><surname>Tuder</surname><given-names>R. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension</article-title>. <source>J. Clin. Invest.</source>
<volume>101</volume>, <fpage>927</fpage>–<lpage>934</lpage>. <pub-id pub-id-type="doi">10.1172/JCI1910</pub-id>
<pub-id pub-id-type="pmid">9486960</pub-id></mixed-citation>
    </ref>
    <ref id="B102">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. S.</given-names></name><name><surname>Collins</surname><given-names>K. M.</given-names></name><name><surname>Brown</surname><given-names>A. L.</given-names></name><name><surname>Lee</surname><given-names>C. H.</given-names></name><name><surname>Chung</surname><given-names>J. H.</given-names></name></person-group> (<year>2000</year>). <article-title>hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response</article-title>. <source>Nature</source>
<volume>404</volume>, <fpage>201</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1038/35004614</pub-id>
<pub-id pub-id-type="pmid">10724175</pub-id></mixed-citation>
    </ref>
    <ref id="B103">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G. Y.</given-names></name><name><surname>Haverty</surname><given-names>P. M.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Kljavin</surname><given-names>N. M.</given-names></name><name><surname>Bourgon</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Comparative oncogenomics identifies psmb4 and shmt2 as potential cancer driver genes</article-title>. <source>Cancer Res.</source>
<volume>74</volume>, <fpage>3114</fpage>–<lpage>3126</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2683</pub-id>
<pub-id pub-id-type="pmid">24755469</pub-id></mixed-citation>
    </ref>
    <ref id="B104">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M. L.</given-names></name><name><surname>Greenberg</surname><given-names>R. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Links between genome integrity and BRCA1 tumor suppression</article-title>. <source>Trends Biochem. Sci.</source>
<volume>37</volume>, <fpage>418</fpage>–<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2012.06.007</pub-id>
<pub-id pub-id-type="pmid">22836122</pub-id></mixed-citation>
    </ref>
    <ref id="B105">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>Integrated analysis of differential expression and alternative splicing of non-small cell lung cancer based on RNA sequencing</article-title>. <source>Oncol. Lett.</source>
<volume>14</volume>, <fpage>1519</fpage>–<lpage>1525</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2017.6300</pub-id>
<pub-id pub-id-type="pmid">28789374</pub-id></mixed-citation>
    </ref>
    <ref id="B106">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Ge</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Transcriptomic and functional network features of lung squamous cell carcinoma through integrative analysis of GEO and TCGA data</article-title>. <source>Sci. Rep.</source>
<volume>8</volume>, <fpage>15834</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-34160-w</pub-id>
<pub-id pub-id-type="pmid">30367091</pub-id></mixed-citation>
    </ref>
    <ref id="B107">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>F. T.</given-names></name><name><surname>Lin</surname><given-names>W. C.</given-names></name></person-group> (<year>2004</year>). <article-title>TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival</article-title>. <source>Genes Dev.</source>
<volume>18</volume>, <fpage>673</fpage>–<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1180204</pub-id>
<pub-id pub-id-type="pmid">15075294</pub-id></mixed-citation>
    </ref>
    <ref id="B108">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Bellam</surname><given-names>N.</given-names></name><name><surname>Lin</surname><given-names>H.-Y.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Stockard</surname><given-names>C. R.</given-names></name><name><surname>Grizzle</surname><given-names>W. E.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in Cancer</article-title>. <source>Mol. Cell. Biol.</source>
<volume>29</volume>, <fpage>2673</fpage>–<lpage>2693</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.01140-08</pub-id>
<pub-id pub-id-type="pmid">19289498</pub-id></mixed-citation>
    </ref>
    <ref id="B109">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y. Z.</given-names></name><name><surname>Jiang</surname><given-names>Y. Y.</given-names></name><name><surname>Hao</surname><given-names>J. J.</given-names></name><name><surname>Lu</surname><given-names>S. S.</given-names></name><name><surname>Zhang</surname><given-names>T. T.</given-names></name><name><surname>Shang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC)</article-title>. <source>Lung Cancer</source>
<volume>77</volume>, <fpage>176</fpage>–<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2012.03.001</pub-id>
<pub-id pub-id-type="pmid">22456526</pub-id></mixed-citation>
    </ref>
    <ref id="B110">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y. Z.</given-names></name><name><surname>Jiang</surname><given-names>Y. Y.</given-names></name><name><surname>Wang</surname><given-names>B. S.</given-names></name><name><surname>Hao</surname><given-names>J. J.</given-names></name><name><surname>Shang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>T. T.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A panel of protein markers for the early detection of lung cancer with bronchial brushing specimens</article-title>. <source>Cancer Cytopathol.</source>
<volume>122</volume>, <fpage>833</fpage>–<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1002/cncy.21461</pub-id>
<pub-id pub-id-type="pmid">25045014</pub-id></mixed-citation>
    </ref>
    <ref id="B111">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>a). <article-title>CHAF1A, the largest subunit of the chromatin assembly factor 1 complex, regulates the growth of H1299 human non-small cell lung cancer cells by inducing G0/G1 cell cycle arrest</article-title>. <source>Exp. Ther. Med.</source>
<volume>14</volume>, <fpage>4681</fpage>–<lpage>4686</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2017.5201</pub-id>
<pub-id pub-id-type="pmid">29201167</pub-id></mixed-citation>
    </ref>
    <ref id="B112">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y. Z.</given-names></name><name><surname>Wang</surname><given-names>B. S.</given-names></name><name><surname>Jiang</surname><given-names>Y. Y.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Hao</surname><given-names>J. J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>b). <article-title>MCMs expression in lung cancer: implication of prognostic significance</article-title>. <source>J. Cancer</source>
<volume>8</volume>, <fpage>3641</fpage>–<lpage>3647</lpage>. <pub-id pub-id-type="doi">10.7150/jca.20777</pub-id>
<pub-id pub-id-type="pmid">29151950</pub-id></mixed-citation>
    </ref>
    <ref id="B113">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>T. P.</given-names></name><name><surname>Tsai</surname><given-names>M. H.</given-names></name><name><surname>Lee</surname><given-names>J. M.</given-names></name><name><surname>Hsu</surname><given-names>C. P.</given-names></name><name><surname>Chen</surname><given-names>P. C.</given-names></name><name><surname>Lin</surname><given-names>C. W.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women</article-title>. <source>Cancer Epidemiol. Biomarkers Prev.</source>
<volume>19</volume>, <fpage>2590</fpage>–<lpage>2597</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-10-0332</pub-id>
<pub-id pub-id-type="pmid">20802022</pub-id></mixed-citation>
    </ref>
    <ref id="B114">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Roman-Campos</surname><given-names>D.</given-names></name><name><surname>Austin</surname><given-names>E. D.</given-names></name><name><surname>Eyries</surname><given-names>M.</given-names></name><name><surname>Sampson</surname><given-names>K. S.</given-names></name><name><surname>Soubrier</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>A novel channelopathy in pulmonary arterial hypertension</article-title>. <source>N. Engl. J. Med.</source>
<volume>369</volume>, <fpage>351</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1211097</pub-id>
<pub-id pub-id-type="pmid">23883380</pub-id></mixed-citation>
    </ref>
    <ref id="B115">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>K.-Y.</given-names></name><name><surname>Schonnesen</surname><given-names>A. A.</given-names></name><name><surname>Brock</surname><given-names>A.</given-names></name><name><surname>Van Den Berg</surname><given-names>C.</given-names></name><name><surname>Eckhardt</surname><given-names>S. G.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response–related genes</article-title>. <source>JCI Insight</source>
<volume>4</volume>, <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.121387</pub-id>
</mixed-citation>
    </ref>
    <ref id="B116">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>R. D.</given-names></name><name><surname>Pauciulo</surname><given-names>M. W.</given-names></name><name><surname>Thomson</surname><given-names>J. R.</given-names></name><name><surname>Lane</surname><given-names>K. B.</given-names></name><name><surname>Morgan</surname><given-names>N. V.</given-names></name><name><surname>Wheeler</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension</article-title>. <source>Am. J. Hum. Genet.</source>
<volume>68</volume>, <fpage>92</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1086/316947</pub-id>
<pub-id pub-id-type="pmid">11115378</pub-id></mixed-citation>
    </ref>
    <ref id="B117">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>J. M.</given-names></name><name><surname>Dusad</surname><given-names>K.</given-names></name><name><surname>Wright</surname><given-names>W. D.</given-names></name><name><surname>Grubb</surname><given-names>J.</given-names></name><name><surname>Budke</surname><given-names>B.</given-names></name><name><surname>Heyer</surname><given-names>W. D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells</article-title>. <source>Nucleic Acids Res.</source>
<volume>43</volume>, <fpage>3180</fpage>–<lpage>3196</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv175</pub-id>
<pub-id pub-id-type="pmid">25765654</pub-id></mixed-citation>
    </ref>
    <ref id="B118">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masri</surname><given-names>F. A.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Comhair</surname><given-names>S. A. A.</given-names></name><name><surname>Asosingh</surname><given-names>K.</given-names></name><name><surname>Koo</surname><given-names>M.</given-names></name><name><surname>Vasanji</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension</article-title>. <source>Am. J. Physiol. - Lung Cell. Mol. Physiol. </source><volume>293</volume>, <fpage>293</fpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00428.2006</pub-id>
</mixed-citation>
    </ref>
    <ref id="B119">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattaini</surname><given-names>K. R.</given-names></name><name><surname>Sullivan</surname><given-names>M. R.</given-names></name><name><surname>Vander Heiden</surname><given-names>M. G.</given-names></name></person-group> (<year>2016</year>). <article-title>The importance of serine metabolism in cancer</article-title>. <source>J. Cell Biol.</source>
<volume>214</volume>, <fpage>249</fpage>–<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201604085</pub-id>
<pub-id pub-id-type="pmid">27458133</pub-id></mixed-citation>
    </ref>
    <ref id="B120">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDaniel</surname><given-names>L. D.</given-names></name><name><surname>Conkrite</surname><given-names>K. L.</given-names></name><name><surname>Chang</surname><given-names>X.</given-names></name><name><surname>Capasso</surname><given-names>M.</given-names></name><name><surname>Vaksman</surname><given-names>Z.</given-names></name><name><surname>Oldridge</surname><given-names>D. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma</article-title>. <source>PloS Genet.</source>
<volume>13</volume>, <fpage>e1006787</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1006787</pub-id>
<pub-id pub-id-type="pmid">28545128</pub-id></mixed-citation>
    </ref>
    <ref id="B121">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMurtry</surname><given-names>M. S.</given-names></name><name><surname>Archer</surname><given-names>S. L.</given-names></name><name><surname>Altieri</surname><given-names>D. C.</given-names></name><name><surname>Bonnet</surname><given-names>S.</given-names></name><name><surname>Haromy</surname><given-names>A.</given-names></name><name><surname>Harry</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension</article-title>. <source>J. Clin. Invest.</source>
<volume>115</volume>, <fpage>1479</fpage>–<lpage>1491</lpage>. <pub-id pub-id-type="doi">10.1172/JCI23203</pub-id>
<pub-id pub-id-type="pmid">15931388</pub-id></mixed-citation>
    </ref>
    <ref id="B122">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montani</surname><given-names>D.</given-names></name><name><surname>Günther</surname><given-names>S.</given-names></name><name><surname>Dorfmüller</surname><given-names>P.</given-names></name><name><surname>Perros</surname><given-names>F.</given-names></name><name><surname>Girerd</surname><given-names>B.</given-names></name><name><surname>Garcia</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Pulmonary arterial hypertension</article-title>. <source>Orphanet J. Rare Dis.</source>
<volume>8</volume>, <fpage>97</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1172-8-97</pub-id>
<pub-id pub-id-type="pmid">23829793</pub-id></mixed-citation>
    </ref>
    <ref id="B123">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrell</surname><given-names>N. W.</given-names></name></person-group> (<year>2006</year>). <article-title>Pulmonary hypertension due to BMPR2 mutation: A new paradigm for tissue remodeling</article-title>. <source>Proc. Am. Thorac. Soc</source>. <fpage>680</fpage>–<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1513/pats.200605-118SF</pub-id>
<pub-id pub-id-type="pmid">17065373</pub-id></mixed-citation>
    </ref>
    <ref id="B124">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mura</surname><given-names>M.</given-names></name><name><surname>Cecchini</surname><given-names>M. J.</given-names></name><name><surname>Joseph</surname><given-names>M.</given-names></name><name><surname>Granton</surname><given-names>J. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension</article-title>. <source>Resp. Resp. </source><volume>32</volume>, <fpage>13557</fpage>. <pub-id pub-id-type="doi">10.1111/resp.13557</pub-id>
</mixed-citation>
    </ref>
    <ref id="B125">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasim</surname><given-names>M. T.</given-names></name><name><surname>Ogo</surname><given-names>T.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Randall</surname><given-names>R.</given-names></name><name><surname>Chowdhury</surname><given-names>H. M.</given-names></name><name><surname>Snape</surname><given-names>K. M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension</article-title>. <source>Hum. Mutat.</source>
<volume>32</volume>, <fpage>1385</fpage>–<lpage>1389</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21605</pub-id>
<pub-id pub-id-type="pmid">21898662</pub-id></mixed-citation>
    </ref>
    <ref id="B126">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>N.</given-names></name><name><surname>Taam</surname><given-names>R. A.</given-names></name><name><surname>Epaud</surname><given-names>R.</given-names></name><name><surname>Delacourt</surname><given-names>C.</given-names></name><name><surname>Deschildre</surname><given-names>A.</given-names></name><name><surname>Reix</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A national internet-linked based database for pediatric interstitial lung diseases: The French network</article-title>. <source>Orphanet J. Rare Dis.</source>
<volume>7</volume>, <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1186/1750-1172-7-40</pub-id>
<pub-id pub-id-type="pmid">22214468</pub-id></mixed-citation>
    </ref>
    <ref id="B127">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>E.</given-names></name><name><surname>Wirtz</surname><given-names>R. M.</given-names></name><name><surname>Kaemmerer</surname><given-names>D.</given-names></name><name><surname>Athelogou</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>L.</given-names></name><name><surname>Sänger</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects</article-title>. <source>Oncotarget</source>
<volume>7</volume>, <fpage>41959</fpage>–<lpage>41973</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.9747</pub-id>
<pub-id pub-id-type="pmid">27259241</pub-id></mixed-citation>
    </ref>
    <ref id="B128">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>J. H.</given-names></name><name><surname>Wheeler</surname><given-names>L.</given-names></name><name><surname>Lane</surname><given-names>K. B.</given-names></name><name><surname>Loyd</surname><given-names>E.</given-names></name><name><surname>Gaddipati</surname><given-names>R.</given-names></name><name><surname>Phillips</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred</article-title>. <source>N. Engl. J. Med.</source>
<volume>345</volume>, <fpage>319</fpage>–<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200108023450502</pub-id>
<pub-id pub-id-type="pmid">11484688</pub-id></mixed-citation>
    </ref>
    <ref id="B129">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oleksiewicz</surname><given-names>U.</given-names></name><name><surname>Liloglou</surname><given-names>T.</given-names></name><name><surname>Tasopoulou</surname><given-names>K. M.</given-names></name><name><surname>Daskoulidou</surname><given-names>N.</given-names></name><name><surname>Gosney</surname><given-names>J. R.</given-names></name><name><surname>Field</surname><given-names>J. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer</article-title>. <source>J. Cancer Res. Clin. Oncol.</source>
<volume>143</volume>, <fpage>1133</fpage>–<lpage>1141</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-017-2381-y</pub-id>
<pub-id pub-id-type="pmid">28258342</pub-id></mixed-citation>
    </ref>
    <ref id="B130">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshlack</surname><given-names>A.</given-names></name><name><surname>Robinson</surname><given-names>M. D.</given-names></name><name><surname>Young</surname><given-names>M. D.</given-names></name></person-group> (<year>2010</year>). <article-title>From RNA-seq reads to differential expression results</article-title>. <source>Genome Biol.</source>
<volume>11</volume>, <fpage>220</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2010-11-12-220</pub-id>
<pub-id pub-id-type="pmid">21176179</pub-id></mixed-citation>
    </ref>
    <ref id="B131">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>A.</given-names></name><name><surname>Gibson</surname><given-names>K.</given-names></name><name><surname>Cisneros</surname><given-names>J.</given-names></name><name><surname>Richards</surname><given-names>T. J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Becerril</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis</article-title>. <source>PloS Med.</source>
<volume>2</volume>, <fpage>0891</fpage>–<lpage>0903</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0020251</pub-id>
</mixed-citation>
    </ref>
    <ref id="B132">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>N. M.</given-names></name><name><surname>Kawut</surname><given-names>S. M.</given-names></name><name><surname>Jelic</surname><given-names>S.</given-names></name><name><surname>Arcasoy</surname><given-names>S. M.</given-names></name><name><surname>Lederer</surname><given-names>D. J.</given-names></name><name><surname>Borczuk</surname><given-names>A. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis</article-title>. <source>Eur. Respir. J.</source>
<volume>41</volume>, <fpage>1324</fpage>–<lpage>1330</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.0084112</pub-id>
<pub-id pub-id-type="pmid">23728404</pub-id></mixed-citation>
    </ref>
    <ref id="B133">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>J. A.</given-names></name><name><surname>Hocott</surname><given-names>J. B.</given-names></name><name><surname>Ebert</surname><given-names>R. V.</given-names></name></person-group> (<year>1961</year>). <article-title>The collagen and elastin content of the lung in emphysema</article-title>. <source>Ann. Intern. Med.</source>
<volume>55</volume>, <fpage>210</fpage>–<lpage>222</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-55-2-210</pub-id>
<pub-id pub-id-type="pmid">13735539</pub-id></mixed-citation>
    </ref>
    <ref id="B134">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pullamsetti</surname><given-names>S. S.</given-names></name><name><surname>Doebele</surname><given-names>C.</given-names></name><name><surname>Fischer</surname><given-names>A.</given-names></name><name><surname>Savai</surname><given-names>R.</given-names></name><name><surname>Kojonazarov</surname><given-names>B.</given-names></name><name><surname>Dahal</surname><given-names>B. K.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>185</volume>, <fpage>409</fpage>–<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201106-1093OC</pub-id>
<pub-id pub-id-type="pmid">22161164</pub-id></mixed-citation>
    </ref>
    <ref id="B135">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putkey</surname><given-names>F. R.</given-names></name><name><surname>Cramer</surname><given-names>T.</given-names></name><name><surname>Morphew</surname><given-names>M. K.</given-names></name><name><surname>Silk</surname><given-names>A. D.</given-names></name><name><surname>Johnson</surname><given-names>R. S.</given-names></name><name><surname>McIntosh</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E</article-title>. <source>Dev. Cell</source>
<volume>3</volume>, <fpage>351</fpage>–<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1016/S1534-5807(02)00255-1</pub-id>
<pub-id pub-id-type="pmid">12361599</pub-id></mixed-citation>
    </ref>
    <ref id="B136">
      <mixed-citation publication-type="webpage"><collab>R. Core Team</collab>. (<year>2019</year>). <source>R: A language and environment for statistical computing</source> (R Foundation for Statistical Computing). Available at: <uri xlink:type="simple" xlink:href="http://www.r-project.org/">http://www.r-project.org/</uri>. </mixed-citation>
    </ref>
    <ref id="B137">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radisky</surname><given-names>D. C.</given-names></name><name><surname>Kenny</surname><given-names>P. A.</given-names></name><name><surname>Bissell</surname><given-names>M. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT</article-title>? <source>J. Cell. Biochem.</source>
<volume>101</volume>, <fpage>830</fpage>–<lpage>839</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.21186</pub-id>
<pub-id pub-id-type="pmid">17211838</pub-id></mixed-citation>
    </ref>
    <ref id="B138">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghu</surname><given-names>G.</given-names></name><name><surname>Nyberg</surname><given-names>F.</given-names></name><name><surname>Morgan</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>The epidemiology of interstitial lung disease and its association with lung cancer</article-title>. <source>Br. J. Cancer</source>
<volume>91</volume>, <fpage>S3</fpage>–<fpage>S10</fpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6602061</pub-id>
<pub-id pub-id-type="pmid">15340372</pub-id></mixed-citation>
    </ref>
    <ref id="B139">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghu</surname><given-names>G.</given-names></name><name><surname>Remy-Jardin</surname><given-names>M.</given-names></name><name><surname>Myers</surname><given-names>J. L.</given-names></name><name><surname>Richeldi</surname><given-names>L.</given-names></name><name><surname>Ryerson</surname><given-names>C. J.</given-names></name><name><surname>Lederer</surname><given-names>D. J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>198</volume>, <fpage>e44</fpage>–<lpage>e68</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201807-1255ST</pub-id>
<pub-id pub-id-type="pmid">30168753</pub-id></mixed-citation>
    </ref>
    <ref id="B140">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>P. R.</given-names></name><name><surname>Cool</surname><given-names>C. D.</given-names></name><name><surname>King</surname><given-names>J. A. C.</given-names></name><name><surname>Stevens</surname><given-names>T.</given-names></name><name><surname>Burns</surname><given-names>N.</given-names></name><name><surname>Winn</surname><given-names>R. A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The cancer paradigm of severe pulmonary arterial hypertension</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>178</volume>, <fpage>558</fpage>–<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200709-1369PP</pub-id>
<pub-id pub-id-type="pmid">18556624</pub-id></mixed-citation>
    </ref>
    <ref id="B141">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redig</surname><given-names>A. J.</given-names></name><name><surname>Capelletti</surname><given-names>M.</given-names></name><name><surname>Dahlberg</surname><given-names>S. E.</given-names></name><name><surname>Sholl</surname><given-names>L. M.</given-names></name><name><surname>Mach</surname><given-names>S.</given-names></name><name><surname>Fontes</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Clinical and molecular characteristics of NF1-mutant lung cancer</article-title>. <source>Clin. Cancer Res.</source>
<volume>22</volume>, <fpage>3148</fpage>–<lpage>3156</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2377</pub-id>
<pub-id pub-id-type="pmid">26861459</pub-id></mixed-citation>
    </ref>
    <ref id="B142">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Relli</surname><given-names>V.</given-names></name><name><surname>Trerotola</surname><given-names>M.</given-names></name><name><surname>Guerra</surname><given-names>E.</given-names></name><name><surname>Alberti</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Distinct lung cancer subtypes associate to distinct drivers of tumor progression</article-title>. <source>Oncotarget</source>
<volume>9</volume>, <fpage>35528</fpage>–<lpage>35540</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.26217</pub-id>
<pub-id pub-id-type="pmid">30473748</pub-id></mixed-citation>
    </ref>
    <ref id="B143">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>C. W.</given-names></name><name><surname>Morgan</surname><given-names>M. A.</given-names></name><name><surname>Bergmann</surname><given-names>L.</given-names></name></person-group> (<year>2000</year>). <article-title>Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies</article-title>? <source>Blood</source>
<volume>96</volume>, <fpage>1655</fpage>–<lpage>1669</lpage>. Available at: <uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10961860">http://www.ncbi.nlm.nih.gov/pubmed/10961860</uri> [Accessed <date-in-citation>July 9, 2019</date-in-citation>].<pub-id pub-id-type="pmid">10961860</pub-id></mixed-citation>
    </ref>
    <ref id="B144">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ristic</surname><given-names>D.</given-names></name><name><surname>Wyman</surname><given-names>C.</given-names></name><name><surname>Paulusma</surname><given-names>C.</given-names></name><name><surname>Kanaar</surname><given-names>R.</given-names></name></person-group> (<year>2002</year>). <article-title>The architecture of the human Rad54-DNA complex provides evidence for protein translocation along DNA</article-title>. <source>Proc. Natl. Acad. Sci.</source>
<volume>98</volume>, <fpage>8454</fpage>–<lpage>8460</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.151056798</pub-id>
</mixed-citation>
    </ref>
    <ref id="B145">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roebroek</surname><given-names>A. J. M.</given-names></name><name><surname>Martens</surname><given-names>G. J. M.</given-names></name><name><surname>Duits</surname><given-names>A. J.</given-names></name><name><surname>Schalken</surname><given-names>J. A.</given-names></name><name><surname>Bokhoven</surname><given-names>A.</given-names></name><name><surname>Wagenaar</surname><given-names>S. S.</given-names></name><etal/></person-group> (<year>1989</year>). <article-title>Differential expression of the gene encoding the novel pituitary polypeptide 7B2 in human lung cancer cells</article-title>. <source>Cancer Res.</source>
<volume>49</volume>, <fpage>4154</fpage>–<lpage>4158</lpage>. Available at: <uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/2545336">http://www.ncbi.nlm.nih.gov/pubmed/2545336</uri> [Accessed <date-in-citation>December 12, 2018</date-in-citation>].<pub-id pub-id-type="pmid">2545336</pub-id></mixed-citation>
    </ref>
    <ref id="B146">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>G.</given-names></name><name><surname>Fiorucci</surname><given-names>G.</given-names></name><name><surname>Chiantore</surname><given-names>M. V.</given-names></name><name><surname>Percario</surname><given-names>Z. A.</given-names></name><name><surname>Vannucchi</surname><given-names>S.</given-names></name><name><surname>Affabris</surname><given-names>E.</given-names></name></person-group> (<year>2002</year>). <article-title>Review: IRF-1 as a negative regulator of cell proliferation</article-title>. <source>J. Interf. Cytokine Res.</source>
<volume>22</volume>, <fpage>39</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1089/107999002753452647</pub-id>
</mixed-citation>
    </ref>
    <ref id="B147">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Tilló</surname><given-names>E.</given-names></name><name><surname>Lázaro</surname><given-names>A.</given-names></name><name><surname>Torrent</surname><given-names>R.</given-names></name><name><surname>Cuatrecasas</surname><given-names>M.</given-names></name><name><surname>Vaquero</surname><given-names>E. C.</given-names></name><name><surname>Castells</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1
</article-title>. <source>Oncogene</source>
<volume>29</volume>, <fpage>3490</fpage>–<lpage>3500</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2010.102</pub-id>
<pub-id pub-id-type="pmid">20418909</pub-id></mixed-citation>
    </ref>
    <ref id="B148">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safe</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>U.-H.</given-names></name><name><surname>Hedrick</surname><given-names>E.</given-names></name><name><surname>Reeder</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>S.-O.</given-names></name></person-group> (<year>2013</year>). <article-title>Minireview: role of orphan nuclear receptors in cancer and potential as drug targets</article-title>. <source>Mol. Endocrinol.</source>
<volume>28</volume>, <fpage>157</fpage>–<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1210/me.2013-1291</pub-id>
<pub-id pub-id-type="pmid">24295738</pub-id></mixed-citation>
    </ref>
    <ref id="B149">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safe</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>U. H.</given-names></name><name><surname>Morpurgo</surname><given-names>B.</given-names></name><name><surname>Abudayyeh</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>M.</given-names></name><name><surname>Tjalkens</surname><given-names>R. B.</given-names></name></person-group> (<year>2016</year>). <article-title>Nuclear receptor 4A (NR4A) family - orphans no more</article-title>. <source>J. Steroid Biochem. Mol. Biol.</source>
<volume>157</volume>, <fpage>48</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2015.04.016</pub-id>
<pub-id pub-id-type="pmid">25917081</pub-id></mixed-citation>
    </ref>
    <ref id="B150">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahara</surname><given-names>M.</given-names></name><name><surname>Sata</surname><given-names>M.</given-names></name><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Hirata</surname><given-names>Y.</given-names></name><name><surname>Nagai</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation</article-title>. <source>Circulation</source>
<volume>115</volume>, <fpage>509</fpage>–<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.655837</pub-id>
<pub-id pub-id-type="pmid">17242277</pub-id></mixed-citation>
    </ref>
    <ref id="B151">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakao</surname><given-names>S.</given-names></name><name><surname>Taraseviciene-Stewart</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>J. D.</given-names></name><name><surname>Wood</surname><given-names>K.</given-names></name><name><surname>Cool</surname><given-names>C. D.</given-names></name><name><surname>Voelkel</surname><given-names>N. F.</given-names></name></person-group> (<year>2005</year>). <article-title>Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells</article-title>. <source>FASEB J.</source>
<volume>19</volume>, <fpage>1178</fpage>–<lpage>1180</lpage>. <pub-id pub-id-type="doi">10.1096/fj.04-3261fje</pub-id>
<pub-id pub-id-type="pmid">15897232</pub-id></mixed-citation>
    </ref>
    <ref id="B152">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauler</surname><given-names>M.</given-names></name><name><surname>Lamontagne</surname><given-names>M.</given-names></name><name><surname>Finnemore</surname><given-names>E.</given-names></name><name><surname>Herazo-Maya</surname><given-names>J. D.</given-names></name><name><surname>Tedrow</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The DNA repair transcriptome in severe COPD</article-title>. <source>Eur. Respir. J.</source>
<volume>52</volume>, <fpage>1701994</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01994-2017</pub-id>
<pub-id pub-id-type="pmid">30190272</pub-id></mixed-citation>
    </ref>
    <ref id="B153">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>M. A.</given-names></name><name><surname>Christopoulos</surname><given-names>P.</given-names></name><name><surname>Muley</surname><given-names>T.</given-names></name><name><surname>Warth</surname><given-names>A.</given-names></name><name><surname>Klingmueller</surname><given-names>U.</given-names></name><name><surname>Thomas</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>a). <article-title>AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients</article-title>. <source>Int. J. Oncol.</source>
<volume>50</volume>, <fpage>365</fpage>–<lpage>372</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2017.3834</pub-id>
<pub-id pub-id-type="pmid">28101582</pub-id></mixed-citation>
    </ref>
    <ref id="B154">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>M. A.</given-names></name><name><surname>Christopoulos</surname><given-names>P.</given-names></name><name><surname>Muley</surname><given-names>T.</given-names></name><name><surname>Warth</surname><given-names>A.</given-names></name><name><surname>Klingmueller</surname><given-names>U.</given-names></name><name><surname>Thomas</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>b). <article-title>AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients</article-title>. <source>Int. J. Oncol.</source>
<volume>50</volume>, <fpage>365</fpage>–<lpage>372</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2017.3834</pub-id>
<pub-id pub-id-type="pmid">28101582</pub-id></mixed-citation>
    </ref>
    <ref id="B155">
      <mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Schwender</surname><given-names>H.</given-names></name></person-group> (<year>2012</year>). <source>siggenes: Multiple testing using SAM and Efron’s empirical Bayes approaches.</source> R package version <fpage>1</fpage><fpage>60</fpage><fpage>0</fpage>
<fpage>1</fpage>–<lpage>70</lpage>. Available at: <uri xlink:type="simple" xlink:href="https://git.bioconductor.org/packages/siggenes">https://git.bioconductor.org/packages/siggenes</uri>. </mixed-citation>
    </ref>
    <ref id="B156">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedic</surname><given-names>M.</given-names></name><name><surname>Skibinski</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>N.</given-names></name><name><surname>Gallardo</surname><given-names>M.</given-names></name><name><surname>Mulligan</surname><given-names>P.</given-names></name><name><surname>Martinez</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence</article-title>. <source>Nat. Commun.</source>
<volume>6</volume>, <fpage>7505</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8505</pub-id>
<pub-id pub-id-type="pmid">26106036</pub-id></mixed-citation>
    </ref>
    <ref id="B157">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Ning</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>CENPE promotes lung adenocarcinoma proliferation and is directly regulated by FOXM1
</article-title>. <source>Int. J. Oncol.</source>
<volume>55</volume>, <fpage>257</fpage>–<lpage>266</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2019.4805</pub-id>
<pub-id pub-id-type="pmid">31115500</pub-id></mixed-citation>
    </ref>
    <ref id="B158">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan Ruan</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Sheng Jiang</surname><given-names>Z.</given-names></name><name><surname>Ming Wang</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Original Article CCNA2 facilitates epithelial-to-mesenchymal transition via the integrin αvβ3 signaling in NSCLC</article-title>. <source>Int. J. Clin. Exp. Pathol</source>. <volume>10</volume> (<issue>8</issue>), <fpage>8324</fpage>–<lpage>8333</lpage>. Available at: www.ijcep.com/[Accessed <date-in-citation>April 3, 2019</date-in-citation>].</mixed-citation>
    </ref>
    <ref id="B159">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P.</given-names></name><name><surname>Markiel</surname><given-names>A.</given-names></name><name><surname>Ozier</surname><given-names>O.</given-names></name><name><surname>Baliga</surname><given-names>N. S.</given-names></name><name><surname>Wang</surname><given-names>J. T.</given-names></name><name><surname>Ramage</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Cytoscape: A software Environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res.</source>
<volume>13</volume>, <fpage>2498</fpage>–<lpage>2504</lpage>. <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
<pub-id pub-id-type="pmid">14597658</pub-id></mixed-citation>
    </ref>
    <ref id="B160">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Miller</surname><given-names>K.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Cancer statistics, 2015
</article-title>. <source>CA Cancer J. Clin.</source>
<volume>65</volume>, <fpage>29</fpage>. <pub-id pub-id-type="doi">10.3322/caac.21254</pub-id>
</mixed-citation>
    </ref>
    <ref id="B161">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigurdsson</surname><given-names>S.</given-names></name><name><surname>Van Komen</surname><given-names>S.</given-names></name><name><surname>Petukhova</surname><given-names>G.</given-names></name><name><surname>Sung</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Homologous DNA pairing by human recombination factors Rad51 and Rad54
</article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>, <fpage>42790</fpage>–<lpage>42794</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M208004200</pub-id>
<pub-id pub-id-type="pmid">12205100</pub-id></mixed-citation>
    </ref>
    <ref id="B162">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soda</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>Y. L.</given-names></name><name><surname>Enomoto</surname><given-names>M.</given-names></name><name><surname>Takada</surname><given-names>S.</given-names></name><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Ishikawa</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title>. <source>Nature</source>
<volume>448</volume>, <fpage>561</fpage>–<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1038/nature05945</pub-id>
<pub-id pub-id-type="pmid">17625570</pub-id></mixed-citation>
    </ref>
    <ref id="B163">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokai</surname><given-names>A.</given-names></name><name><surname>Handa</surname><given-names>T.</given-names></name><name><surname>Tanizawa</surname><given-names>K.</given-names></name><name><surname>Oga</surname><given-names>T.</given-names></name><name><surname>Uno</surname><given-names>K.</given-names></name><name><surname>Tsuruyama</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis</article-title>. <source>Respir. Res.</source>
<volume>16</volume>, <fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1186/s12931-015-0280-9</pub-id>
<pub-id pub-id-type="pmid">25567521</pub-id></mixed-citation>
    </ref>
    <ref id="B164">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y.-J.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>X.-H.</given-names></name><name><surname>Wang</surname><given-names>L.-X.</given-names></name></person-group> (<year>2018</year>). <article-title>Integrated analysis reveals key genes with prognostic value in lung adenocarcinoma</article-title>. <source>Cancer Manage. Res.</source>
<volume>10</volume>, <fpage>6097</fpage>–<lpage>6108</lpage>. <pub-id pub-id-type="doi">10.2147/CMAR.S168636</pub-id>
</mixed-citation>
    </ref>
    <ref id="B165">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soria</surname><given-names>J. C.</given-names></name><name><surname>Jang</surname><given-names>S. J.</given-names></name><name><surname>Khuri</surname><given-names>F. R.</given-names></name><name><surname>Hassan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Hong</surname><given-names>W. K.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication</article-title>. <source>Cancer Res.</source>
<volume>60</volume>, <fpage>4000</fpage>–<lpage>4004</lpage>. Available at: <uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10945597">http://www.ncbi.nlm.nih.gov/pubmed/10945597</uri> [Accessed <date-in-citation>June 20, 2019</date-in-citation>].<pub-id pub-id-type="pmid">10945597</pub-id></mixed-citation>
    </ref>
    <ref id="B166">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotgia</surname><given-names>F.</given-names></name><name><surname>Lisanti</surname><given-names>M. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: use as companion diagnostics</article-title>. <source>Oncotarget</source>
<volume>8</volume>, <fpage>68095</fpage>–<lpage>68107</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.19677</pub-id>
<pub-id pub-id-type="pmid">28978099</pub-id></mixed-citation>
    </ref>
    <ref id="B167">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spagnolo</surname><given-names>P.</given-names></name><name><surname>Grunewald</surname><given-names>J.</given-names></name><name><surname>Du Bois</surname><given-names>R. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Genetic determinants of pulmonary fibrosis: evolving concepts</article-title>. <source>Lancet Respir. Med.</source>
<volume>2</volume>, <fpage>416</fpage>–<lpage>428</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(14)70047-5</pub-id>
<pub-id pub-id-type="pmid">24815806</pub-id></mixed-citation>
    </ref>
    <ref id="B168">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spira</surname><given-names>A.</given-names></name><name><surname>Beane</surname><given-names>J.</given-names></name><name><surname>Pinto-Plata</surname><given-names>V.</given-names></name><name><surname>Kadar</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Shah</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Gene expression profiling of human lung tissue from smokers with severe emphysema</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source>
<volume>31</volume>, <fpage>601</fpage>–<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2004-0273OC</pub-id>
<pub-id pub-id-type="pmid">15374838</pub-id></mixed-citation>
    </ref>
    <ref id="B169">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadler</surname><given-names>Z. K.</given-names></name><name><surname>Thom</surname><given-names>P.</given-names></name><name><surname>Robson</surname><given-names>M. E.</given-names></name><name><surname>Weitzel</surname><given-names>J. N.</given-names></name><name><surname>Kauff</surname><given-names>N. D.</given-names></name><name><surname>Hurley</surname><given-names>K. E.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Genome-wide association studies of cancer</article-title>. <source>J. Clin. Oncol. </source><volume>28</volume>, <fpage>4255</fpage>–<lpage>4267</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2009.25.7816.</pub-id>
<pub-id pub-id-type="pmid">20585100</pub-id></mixed-citation>
    </ref>
    <ref id="B170">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>M. K.</given-names></name><name><surname>Syrkina</surname><given-names>O. L.</given-names></name><name><surname>Kolliputi</surname><given-names>N.</given-names></name><name><surname>Mark</surname><given-names>E. J.</given-names></name><name><surname>Hales</surname><given-names>C. A.</given-names></name><name><surname>Waxman</surname><given-names>A. B.</given-names></name></person-group> (<year>2009</year>). <article-title>Interleukin-6 overexpression induces pulmonary hypertension</article-title>. <source>Circ. Res.</source>
<volume>104</volume>, <fpage>236</fpage>–<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.182014</pub-id>
<pub-id pub-id-type="pmid">19074475</pub-id></mixed-citation>
    </ref>
    <ref id="B171">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>R. M.</given-names></name><name><surname>Banchereau</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Taking dendritic cells into medicine</article-title>. <source>Nature</source>
<volume>449</volume>, <fpage>419</fpage>–<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1038/nature06175</pub-id>
<pub-id pub-id-type="pmid">17898760</pub-id></mixed-citation>
    </ref>
    <ref id="B172">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>L. E.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Nguyen</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). “<article-title>A novel molecular subset of metastatic lung adenocarcinoma is defined by the function of the proteoglycan receptor HMMR</article-title>,” in <source>Tumor Biology</source> (<publisher-name>American Association for Cancer Research</publisher-name>), <fpage>2269</fpage>–<lpage>2269</lpage>. <pub-id pub-id-type="doi">10.1158/1538-7445.am2015-2269</pub-id>
</mixed-citation>
    </ref>
    <ref id="B173">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>L. E.</given-names></name><name><surname>Cheung</surname><given-names>W. K. C.</given-names></name><name><surname>Adua</surname><given-names>S. J.</given-names></name><name><surname>Arnal-Estapé</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Extracellular matrix receptor expression in subtypes of lung adenocarcinoma potentiates outgrowth of micrometastases</article-title>. <source>Cancer Res.</source>
<volume>77</volume>, <fpage>1905</fpage>–<lpage>1917</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1978</pub-id>
<pub-id pub-id-type="pmid">28196904</pub-id></mixed-citation>
    </ref>
    <ref id="B174">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoimenov</surname><given-names>I.</given-names></name><name><surname>Helleday</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>PCNA on the crossroad of cancer</article-title>. <source>Biochem. Soc Trans.</source>
<volume>37</volume>, <fpage>605</fpage>–<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1042/BST0370605</pub-id>
<pub-id pub-id-type="pmid">19442257</pub-id></mixed-citation>
    </ref>
    <ref id="B175">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sud</surname><given-names>A.</given-names></name><name><surname>Kinnersley</surname><given-names>B.</given-names></name><name><surname>Houlston</surname><given-names>R. S.</given-names></name></person-group> (<year>2017</year>). <article-title>Genome-wide association studies of cancer: current insights and future perspectives</article-title>. <source>Nat. Rev. Cancer</source>
<volume>17</volume>, <fpage>692</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1038/nrc.2017.82</pub-id>
<pub-id pub-id-type="pmid">29026206</pub-id></mixed-citation>
    </ref>
    <ref id="B176">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C. C.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>W.-D.</given-names></name><name><surname>Li</surname><given-names>S. J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Z. L.</given-names></name><etal/></person-group> (<year>2018</year>a). <article-title>Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma</article-title>. <source>Aging (Albany. NY).</source>
<volume>10</volume>, <fpage>973</fpage>–<lpage>987</lpage>. <pub-id pub-id-type="doi">10.18632/aging.101441</pub-id>
<pub-id pub-id-type="pmid">29754146</pub-id></mixed-citation>
    </ref>
    <ref id="B177">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>F.</given-names></name><name><surname>Yin</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>b). <article-title>Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer</article-title>. <source>Oncol. Lett.</source>
<volume>16</volume>, <fpage>2201</fpage>–<lpage>2206</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.8938</pub-id>
<pub-id pub-id-type="pmid">30008919</pub-id></mixed-citation>
    </ref>
    <ref id="B178">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutendra</surname><given-names>G.</given-names></name><name><surname>Bonnet</surname><given-names>S.</given-names></name><name><surname>Rochefort</surname><given-names>G.</given-names></name><name><surname>Haromy</surname><given-names>A.</given-names></name><name><surname>Folmes</surname><given-names>K. D.</given-names></name><name><surname>Lopaschuk</surname><given-names>G. D.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension</article-title>. <source>Sci. Transl. Med.</source>
<volume>2</volume>, <fpage>44ra58</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3001327</pub-id>
</mixed-citation>
    </ref>
    <ref id="B179">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swagemakers</surname><given-names>S. M.</given-names></name><name><surname>Essers</surname><given-names>J.</given-names></name><name><surname>de Wit</surname><given-names>J.</given-names></name><name><surname>Hoeijmakers</surname><given-names>J. H.</given-names></name><name><surname>Kanaar</surname><given-names>R.</given-names></name></person-group> (<year>1998</year>). <article-title>The human RAD54 recombinational DNA repair protein is a double-stranded DNA-dependent ATPase</article-title>. <source>J. Biol. Chem.</source>
<volume>273</volume>, <fpage>28292</fpage>–<lpage>28297</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.273.43.28292</pub-id>
<pub-id pub-id-type="pmid">9774452</pub-id></mixed-citation>
    </ref>
    <ref id="B180">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>D. F.</given-names></name><name><surname>Huberman</surname><given-names>J. A.</given-names></name><name><surname>Hyland</surname><given-names>A.</given-names></name><name><surname>Loewen</surname><given-names>G. M.</given-names></name><name><surname>Brooks</surname><given-names>J. S.</given-names></name><name><surname>Beck</surname><given-names>A. F.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>MCM2 - A promising marker for premalignant lesions of the lung: A cohort study</article-title>. <source>BMC Cancer</source>
<volume>1</volume>, <fpage>6</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-1-6</pub-id>
<pub-id pub-id-type="pmid">11472637</pub-id></mixed-citation>
    </ref>
    <ref id="B181">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>N.</given-names></name><name><surname>Ishihara</surname><given-names>M.</given-names></name><name><surname>Lamphier</surname><given-names>M. S.</given-names></name><name><surname>Nozawa</surname><given-names>H.</given-names></name><name><surname>Matsuyama</surname><given-names>T.</given-names></name><name><surname>Mak</surname><given-names>T. W.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage</article-title>. <source>Nature</source>
<volume>382</volume>, <fpage>816</fpage>–<lpage>818</lpage>. <pub-id pub-id-type="doi">10.1038/382816a0</pub-id>
<pub-id pub-id-type="pmid">8752276</pub-id></mixed-citation>
    </ref>
    <ref id="B182">
      <mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Tibshirani</surname><given-names>R.</given-names></name><name><surname>Michael</surname><given-names>J.</given-names></name><name><surname>Seo</surname><given-names>G.</given-names></name><name><surname>Balasubramanian</surname></name><name><surname>Chu</surname></name><name><surname>Narasimhan</surname><given-names>J. L.</given-names></name></person-group> (<year>2018</year>). <article-title>samr: SAM: significance analysis of microarrays</article-title>. Available at: <uri xlink:type="simple" xlink:href="https://cran.r-project.org/package=samr">https://cran.r-project.org/package=samr</uri>. </mixed-citation>
    </ref>
    <ref id="B183">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tishkoff</surname><given-names>D. X.</given-names></name><name><surname>Filosi</surname><given-names>N.</given-names></name><name><surname>Gaida</surname><given-names>G. M.</given-names></name><name><surname>Kolodner</surname><given-names>R. D.</given-names></name></person-group> (<year>1997</year>). <article-title>A novel mutation avoidance mechanism dependent on S. cerevisiae RAD27 is distinct from DNA mismatch repair</article-title>. <source>Cell</source>
<volume>88</volume>, <fpage>253</fpage>–<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81846-2</pub-id>
<pub-id pub-id-type="pmid">9008166</pub-id></mixed-citation>
    </ref>
    <ref id="B184">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trembath</surname><given-names>R. C.</given-names></name><name><surname>Thomson</surname><given-names>J. R.</given-names></name><name><surname>Machado</surname><given-names>R. D.</given-names></name><name><surname>Morgan</surname><given-names>N. V.</given-names></name><name><surname>Atkinson</surname><given-names>C.</given-names></name><name><surname>Winship</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia</article-title>. <source>N. Engl. J. Med.</source>
<volume>345</volume>, <fpage>325</fpage>–<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200108023450503</pub-id>
<pub-id pub-id-type="pmid">11484689</pub-id></mixed-citation>
    </ref>
    <ref id="B185">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>L.</given-names></name><name><surname>De Man</surname><given-names>F. S.</given-names></name><name><surname>Girerd</surname><given-names>B.</given-names></name><name><surname>Huertas</surname><given-names>A.</given-names></name><name><surname>Chaumais</surname><given-names>M. C.</given-names></name><name><surname>Lecerf</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A critical role for p130 Cas in the progression of pulmonary hypertension in humans and rodents</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>186</volume>, <fpage>666</fpage>–<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201202-0309OC</pub-id>
<pub-id pub-id-type="pmid">22798315</pub-id></mixed-citation>
    </ref>
    <ref id="B186">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuder</surname><given-names>R. M.</given-names></name><name><surname>Cool</surname><given-names>C. D.</given-names></name><name><surname>Yeager</surname><given-names>M.</given-names></name><name><surname>Taraseviciene-Stewart</surname><given-names>L.</given-names></name><name><surname>Bull</surname><given-names>T. M.</given-names></name><name><surname>Voelkel</surname><given-names>N. F.</given-names></name></person-group> (<year>2001</year>). <article-title>The pathobiology of pulmonary hypertension: Endothelium</article-title>. <source>Clin. Chest Med.</source>
<volume>22</volume>, <fpage>405</fpage>–<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1016/S0272-5231(05)70280-X</pub-id>
<pub-id pub-id-type="pmid">11590837</pub-id></mixed-citation>
    </ref>
    <ref id="B187">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuder</surname><given-names>R. M.</given-names></name><name><surname>Davis</surname><given-names>L. A.</given-names></name><name><surname>Graham</surname><given-names>B. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeting energetic metabolism: A new frontier in the pathogenesis and treatment of pulmonary hypertension</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>185</volume>, <fpage>260</fpage>–<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201108-1536PP</pub-id>
<pub-id pub-id-type="pmid">22077069</pub-id></mixed-citation>
    </ref>
    <ref id="B188">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Välk</surname><given-names>K.</given-names></name><name><surname>Vooder</surname><given-names>T.</given-names></name><name><surname>Kolde</surname><given-names>R.</given-names></name><name><surname>Reintam</surname><given-names>M. A.</given-names></name><name><surname>Petzold</surname><given-names>C.</given-names></name><name><surname>Vilo</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers</article-title>. <source>Oncology</source>
<volume>79</volume>, <fpage>283</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1159/000322116</pub-id>
</mixed-citation>
    </ref>
    <ref id="B189">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Duijnhoven</surname><given-names>H. L. P.</given-names></name><name><surname>Vissers</surname><given-names>P. M. A. M.</given-names></name><name><surname>Timmer</surname><given-names>E. D. J.</given-names></name><name><surname>Groeneveld</surname><given-names>A.</given-names></name><name><surname>Van De Ven</surname><given-names>W. J. M.</given-names></name></person-group> (<year>1991</year>). <article-title>The 7B2 protein as marker for neuroendocrine differentiation in human lung cancer</article-title>. <source>Br. J. Cancer</source>
<volume>63</volume>, <fpage>4154</fpage> Available at: <uri xlink:type="simple" xlink:href="https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2204091&amp;blobtype=pdf">https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2204091&amp;blobtype=pdf</uri> [Accessed <date-in-citation>December 12, 2018</date-in-citation>].</mixed-citation>
    </ref>
    <ref id="B190">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigouroux</surname><given-names>C.</given-names></name><name><surname>Casse</surname><given-names>J. M.</given-names></name><name><surname>Battaglia-Hsu</surname><given-names>S. F.</given-names></name><name><surname>Brochin</surname><given-names>L.</given-names></name><name><surname>Luc</surname><given-names>A.</given-names></name><name><surname>Paris</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma</article-title>. <source>Lung Cancer</source>
<volume>89</volume>, <fpage>189</fpage>–<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2015.05.008</pub-id>
<pub-id pub-id-type="pmid">26013954</pub-id></mixed-citation>
    </ref>
    <ref id="B191">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vukmirovic</surname><given-names>M.</given-names></name><name><surname>Kaminski</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Impact of transcriptomics on our understanding of pulmonary fibrosis</article-title>. <source>Front. Med.</source>
<volume>5</volume>, <fpage>87</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2018.00087</pub-id>
</mixed-citation>
    </ref>
    <ref id="B192">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wachi</surname><given-names>S.</given-names></name><name><surname>Yoneda</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues</article-title>. <source>Bioinformatics</source>
<volume>21</volume>, <fpage>4205</fpage>–<lpage>4208</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bti688</pub-id>
<pub-id pub-id-type="pmid">16188928</pub-id></mixed-citation>
    </ref>
    <ref id="B193">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Liotta</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Clinical bioinformatics: a new emerging science</article-title>. <source>J. Clin. Bioinforma.</source>
<volume>1</volume>, <fpage>1</fpage>. <pub-id pub-id-type="doi">10.1186/2043-9113-1-1</pub-id>
</mixed-citation>
    </ref>
    <ref id="B194">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Matsuoka</surname><given-names>S.</given-names></name><name><surname>Ballif</surname><given-names>B. A.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Smogorzewska</surname><given-names>A.</given-names></name><name><surname>Gygi</surname><given-names>S. P.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response</article-title>. <source>Science</source> (80-.), <fpage>1194</fpage>–<lpage>1198</lpage>. <pub-id pub-id-type="doi">10.1126/science.1139476</pub-id>
<pub-id pub-id-type="pmid">17525340</pub-id></mixed-citation>
    </ref>
    <ref id="B195">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>I. M.</given-names></name><name><surname>Stepaniants</surname><given-names>S.</given-names></name><name><surname>Boie</surname><given-names>Y.</given-names></name><name><surname>Mortimer</surname><given-names>J. R.</given-names></name><name><surname>Kennedy</surname><given-names>B.</given-names></name><name><surname>Elliott</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>177</volume>, <fpage>402</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200703-390OC</pub-id>
<pub-id pub-id-type="pmid">17975202</pub-id></mixed-citation>
    </ref>
    <ref id="B196">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Zhong</surname><given-names>Q.</given-names></name><name><surname>Zhan</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Candidate genes and pathogenesis investigation for sepsis-related acute respiratory distress syndrome based on gene expression profile</article-title>. <source>Biol. Res.</source>
<volume>49</volume>, <fpage>25</fpage>. <pub-id pub-id-type="doi">10.1186/s40659-016-0085-4</pub-id>
<pub-id pub-id-type="pmid">27090785</pub-id></mixed-citation>
    </ref>
    <ref id="B197">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warth</surname><given-names>A.</given-names></name><name><surname>Cortis</surname><given-names>J.</given-names></name><name><surname>Soltermann</surname><given-names>A.</given-names></name><name><surname>Meister</surname><given-names>M.</given-names></name><name><surname>Budczies</surname><given-names>J.</given-names></name><name><surname>Stenzinger</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role</article-title>. <source>Br. J. Cancer</source>
<volume>111</volume>, <fpage>1222</fpage>–<lpage>1229</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2014.402</pub-id>
<pub-id pub-id-type="pmid">25051406</pub-id></mixed-citation>
    </ref>
    <ref id="B198">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellner</surname><given-names>U.</given-names></name><name><surname>Schubert</surname><given-names>J.</given-names></name><name><surname>Burk</surname><given-names>U. C.</given-names></name><name><surname>Schmalhofer</surname><given-names>O.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Sonntag</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs</article-title>. <source>Nat. Cell Biol.</source>
<volume>11</volume>, <fpage>1487</fpage>–<lpage>1495</lpage>. <pub-id pub-id-type="doi">10.1038/ncb1998</pub-id>
<pub-id pub-id-type="pmid">19935649</pub-id></mixed-citation>
    </ref>
    <ref id="B199">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>B. C.</given-names></name><name><surname>Borok</surname><given-names>Z.</given-names></name></person-group> (<year>2009</year>). <article-title>Epithelial-mesenchymal transition: Potential role in obliterative bronchiolitis</article-title>? <source>Thorax</source>
<volume>64</volume>, <fpage>742</fpage>–<lpage>743</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2009.114413</pub-id>
<pub-id pub-id-type="pmid">19717708</pub-id></mixed-citation>
    </ref>
    <ref id="B200">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willuda</surname><given-names>J.</given-names></name><name><surname>Linden</surname><given-names>L.</given-names></name><name><surname>Lerchen</surname><given-names>H.-G.</given-names></name><name><surname>Kopitz</surname><given-names>C.</given-names></name><name><surname>Stelte-Ludwig</surname><given-names>B.</given-names></name><name><surname>Pena</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer</article-title>. <source>Mol. Cancer Ther.</source>
<volume>16</volume>, <fpage>893</fpage>–<lpage>904</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0474</pub-id>
<pub-id pub-id-type="pmid">28292941</pub-id></mixed-citation>
    </ref>
    <ref id="B201">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>O’Connell</surname><given-names>P.</given-names></name><name><surname>Viskochil</surname><given-names>D.</given-names></name><name><surname>Cawthon</surname><given-names>R.</given-names></name><name><surname>Robertson</surname><given-names>M.</given-names></name><name><surname>Culver</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1990</year>). <article-title>The neurofibromatosis type 1 gene encodes a protein related to GAP</article-title>. <source>Cell</source>
<volume>62</volume>, <fpage>599</fpage>–<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(90)90024-9</pub-id>
<pub-id pub-id-type="pmid">2116237</pub-id></mixed-citation>
    </ref>
    <ref id="B202">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Koeck</surname><given-names>T.</given-names></name><name><surname>Lara</surname><given-names>A. R.</given-names></name><name><surname>Neumann</surname><given-names>D.</given-names></name><name><surname>DiFilippo</surname><given-names>F. P.</given-names></name><name><surname>Koo</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Alterations of cellular bioenergetics in pulmonary artery endothelial cells</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>104</volume>, <fpage>1342</fpage>–<lpage>1347</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0605080104</pub-id>
<pub-id pub-id-type="pmid">17227868</pub-id></mixed-citation>
    </ref>
    <ref id="B203">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Bi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Hou</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Integrative analysis of multi-omics data reveals distinct impacts of DDB1-CUL4 associated factors in human lung adenocarcinomas</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>333</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-00512-1</pub-id>
<pub-id pub-id-type="pmid">28336923</pub-id></mixed-citation>
    </ref>
    <ref id="B204">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Ramnath</surname><given-names>N.</given-names></name><name><surname>Moysich</surname><given-names>K. B.</given-names></name><name><surname>Asch</surname><given-names>H. L.</given-names></name><name><surname>Swede</surname><given-names>H.</given-names></name><name><surname>Alrawi</surname><given-names>S. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer</article-title>. <source>BMC Cancer</source>
<volume>6</volume>, <fpage>203</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-6-203</pub-id>
<pub-id pub-id-type="pmid">16882345</pub-id></mixed-citation>
    </ref>
    <ref id="B205">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Wheeler</surname><given-names>S. E.</given-names></name><name><surname>Velikoff</surname><given-names>M.</given-names></name><name><surname>Kleaveland</surname><given-names>K. R.</given-names></name><name><surname>Lafemina</surname><given-names>M. J.</given-names></name><name><surname>Frank</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Activated alveolar epithelial cells initiate fibrosis through secretion of mesenchymal proteins</article-title>. <source>Am. J. Pathol.</source>
<volume>183</volume>, <fpage>1559</fpage>–<lpage>1570</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2013.07.016</pub-id>
<pub-id pub-id-type="pmid">24012677</pub-id></mixed-citation>
    </ref>
    <ref id="B206">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeager</surname><given-names>M. E.</given-names></name><name><surname>Halley</surname><given-names>G. R.</given-names></name><name><surname>Golpon</surname><given-names>H. A.</given-names></name><name><surname>Voelkel</surname><given-names>N. F.</given-names></name><name><surname>Tuder</surname><given-names>R. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension</article-title>. <source>Circ. Res.</source>
<volume>88</volume>, <fpage>E2</fpage>–<fpage>E11</fpage>. <pub-id pub-id-type="doi">10.1161/01.res.88.1.e2</pub-id>
<pub-id pub-id-type="pmid">11139485</pub-id></mixed-citation>
    </ref>
    <ref id="B207">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeager</surname><given-names>M. E.</given-names></name><name><surname>Frid</surname><given-names>M. G.</given-names></name><name><surname>Stenmark</surname><given-names>K. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Progenitor cells in pulmonary vascular remodeling</article-title>. <source>Pulm. Circ.</source>
<volume>1</volume>, <fpage>3</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.4103/2045-8932.78095</pub-id>
<pub-id pub-id-type="pmid">22034593</pub-id></mixed-citation>
    </ref>
    <ref id="B208">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>J. E.</given-names></name><name><surname>Toniolo</surname><given-names>P. A.</given-names></name><name><surname>Frank</surname><given-names>D. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting transcription factors: promising new strategies for cancer therapy</article-title>. <source>Curr. Opin. Oncol.</source>
<volume>25</volume>, <fpage>652</fpage>–<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1097/01.cco.0000432528.88101.1a</pub-id>
<pub-id pub-id-type="pmid">24048019</pub-id></mixed-citation>
    </ref>
    <ref id="B209">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>W.</given-names></name><name><surname>Dai</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Liao</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1
</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>4430</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-04818-y</pub-id>
<pub-id pub-id-type="pmid">28667340</pub-id></mixed-citation>
    </ref>
    <ref id="B210">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yochum</surname><given-names>Z.</given-names></name><name><surname>Socinski</surname><given-names>M.</given-names></name><name><surname>Burns</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance</article-title>. <source>J. Thorac. Dis.</source>
<volume>6</volume>, <fpage>S152</fpage>–<fpage>S161</fpage>. <pub-id pub-id-type="doi">10.21037/jtd.2016.11.59</pub-id>
</mixed-citation>
    </ref>
    <ref id="B211">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoder</surname><given-names>M. C.</given-names></name><name><surname>Mead</surname><given-names>L. E.</given-names></name><name><surname>Prater</surname><given-names>D.</given-names></name><name><surname>Krier</surname><given-names>T. R.</given-names></name><name><surname>Mroueh</surname><given-names>K. N.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals</article-title>. <source>Blood</source>
<volume>109</volume> (<issue>5</issue>), <fpage>1801</fpage>–<lpage>1809</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2006-08-043471</pub-id>
<pub-id pub-id-type="pmid">17053059</pub-id></mixed-citation>
    </ref>
    <ref id="B212">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Inoue</surname><given-names>I.</given-names></name></person-group> (<year>2004</year>). <article-title>Expression of MCM10 and TopBP1 is regulated by cell proliferation and UV irradiation via the E2F transcription factor</article-title>. <source>Oncogene</source>
<volume>23</volume>, <fpage>6250</fpage>–<lpage>6260</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1207829</pub-id>
<pub-id pub-id-type="pmid">15195143</pub-id></mixed-citation>
    </ref>
    <ref id="B213">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Wilson</surname><given-names>J.</given-names></name><name><surname>Taylor</surname><given-names>L.</given-names></name><name><surname>Polgar</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>DNA microarray and signal transduction analysis in pulmonary artery smooth muscle cells from heritable and idiopathic pulmonary arterial hypertension subjects</article-title>. <source>J. Cell. Biochem.</source>
<volume>116</volume>, <fpage>386</fpage>–<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.24987</pub-id>
<pub-id pub-id-type="pmid">25290246</pub-id></mixed-citation>
    </ref>
    <ref id="B214">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group> (<year>2017</year>). <article-title>LncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1
</article-title>. <source>Cancer Gene Ther.</source>
<volume>24</volume>, <fpage>221</fpage>–<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1038/cgt.2017.10</pub-id>
<pub-id pub-id-type="pmid">28429752</pub-id></mixed-citation>
    </ref>
    <ref id="B215">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L.-H.</given-names></name><name><surname>Huang</surname><given-names>Q.-W.</given-names></name><name><surname>Zhou</surname><given-names>X.-H.</given-names></name></person-group> (<year>2019</year>a). <article-title>Identification of Cancer Hallmarks Based on the Gene Co-expression Networks of Seven Cancers</article-title>. <source>Front. Genet.</source>
<volume>10</volume>, <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.3389/fgene.2019.00099</pub-id>
<pub-id pub-id-type="pmid">30804975</pub-id></mixed-citation>
    </ref>
    <ref id="B216">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L. H.</given-names></name><name><surname>Huang</surname><given-names>Q. W.</given-names></name><name><surname>Zhou</surname><given-names>X. H.</given-names></name></person-group> (<year>2019</year>b). <article-title>Identification of cancer hallmarks based on the gene co-expression networks of seven cancers</article-title>. <source>Front. Genet.</source>
<volume>10</volume>, <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.3389/fgene.2019.00099</pub-id>
<pub-id pub-id-type="pmid">30804975</pub-id></mixed-citation>
    </ref>
    <ref id="B217">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W. C.</given-names></name><name><surname>Ng</surname><given-names>S. C.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Rai</surname><given-names>A.</given-names></name><name><surname>Umashankar</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis</article-title>. <source>Cell</source>
<volume>148</volume>, <fpage>259</fpage>–<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.11.050</pub-id>
<pub-id pub-id-type="pmid">22225612</pub-id></mixed-citation>
    </ref>
    <ref id="B218">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Creighton</surname><given-names>C. J.</given-names></name><name><surname>Lu</surname><given-names>Q.</given-names></name><name><surname>Gibbons</surname><given-names>D. L.</given-names></name><name><surname>Yi</surname><given-names>E. S.</given-names></name><etal/></person-group> (<year>2016</year>a). <article-title>A genetic cell context-dependent role for ZEB1 in lung cancer</article-title>. <source>Nat. Commun.</source>
<volume>7</volume>, <fpage>12231</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms12231</pub-id>
<pub-id pub-id-type="pmid">27456471</pub-id></mixed-citation>
    </ref>
    <ref id="B219">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Mao</surname><given-names>J. H.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Jain</surname><given-names>A. K.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Brown</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2016</year>b). <article-title>Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy</article-title>. <source>Nat. Commun.</source>
<volume>7</volume>, <fpage>12619</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms12619</pub-id>
<pub-id pub-id-type="pmid">27577169</pub-id></mixed-citation>
    </ref>
    <ref id="B220">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>A.</given-names></name><name><surname>Hydbring</surname><given-names>P.</given-names></name><name><surname>Ambroise</surname><given-names>G.</given-names></name><name><surname>Ouchida</surname><given-names>A. T.</given-names></name><name><surname>Goiny</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis</article-title>. <source>Cell Rep.</source>
<volume>19</volume>, <fpage>2289</fpage>–<lpage>2303</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.05.067</pub-id>
<pub-id pub-id-type="pmid">28614715</pub-id></mixed-citation>
    </ref>
    <ref id="B221">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Keymeulen</surname><given-names>S.</given-names></name><name><surname>Nelson</surname><given-names>R.</given-names></name><name><surname>Tong</surname><given-names>T. R.</given-names></name><name><surname>Yuan</surname><given-names>Y. C.</given-names></name><name><surname>Yun</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2018</year>a). <article-title>Overexpression of flap endonuclease 1 correlates with enhanced proliferation and poor prognosis of non–small-cell lung cancer</article-title>. <source>Am. J. Pathol.</source>
<volume>188</volume>, <fpage>242</fpage>–<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2017.09.011</pub-id>
<pub-id pub-id-type="pmid">29037854</pub-id></mixed-citation>
    </ref>
    <ref id="B222">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M. Y.</given-names></name><name><surname>Liu</surname><given-names>X. X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>Y. Q.</given-names></name></person-group> (<year>2018</year>b). <article-title>Elevated mRNA levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis</article-title>. <source>Int. J. Med. Sci.</source>
<volume>15</volume>, <fpage>1676</fpage>–<lpage>1685</lpage>. <pub-id pub-id-type="doi">10.7150/ijms.28728</pub-id>
<pub-id pub-id-type="pmid">30588191</pub-id></mixed-citation>
    </ref>
    <ref id="B223">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Qiao</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name></person-group> (<year>2018</year>c). <article-title>SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma</article-title>. <source>Oncol. Lett.</source>
<volume>15</volume>, <fpage>7028</fpage>–<lpage>7036</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.8235</pub-id>
<pub-id pub-id-type="pmid">29849788</pub-id></mixed-citation>
    </ref>
    <ref id="B224">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>P.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2007</year>a). <article-title>Fen1 mutations result in autoimmunity, chronic inflammation and cancers</article-title>. <source>Nat. Med.</source>
<volume>13</volume>, <fpage>812</fpage>–<lpage>819</lpage>. <pub-id pub-id-type="doi">10.1038/nm1599</pub-id>
<pub-id pub-id-type="pmid">17589521</pub-id></mixed-citation>
    </ref>
    <ref id="B225">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Haura</surname><given-names>E.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Bepler</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>b). <article-title>DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer</article-title>. <source>N. Engl. J. Med.</source>
<volume>356</volume>, <fpage>800</fpage>–<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa065411</pub-id>
<pub-id pub-id-type="pmid">17314339</pub-id></mixed-citation>
    </ref>
    <ref id="B226">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X. H.</given-names></name><name><surname>Chu</surname><given-names>X. Y.</given-names></name><name><surname>Xue</surname><given-names>G.</given-names></name><name><surname>Xiong</surname><given-names>J. H.</given-names></name><name><surname>Zhang</surname><given-names>H. Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Identifying cancer prognostic modules by module network analysis</article-title>. <source>BMC Bioinf.</source>
<volume>20</volume>, <fpage>85</fpage>. <pub-id pub-id-type="doi">10.1186/s12859-019-2674-z</pub-id>
</mixed-citation>
    </ref>
    <ref id="B227">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y. F.</given-names></name><name><surname>Zheng</surname><given-names>S. Y.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Clinicopathological significance of E-cadherin and PCNA expression in hunman non-small cell lung cancer. in 2010 4th International Conference on Bioinformatics and Biomedical Engineering, iCBBE 2010
</article-title>. <source>Chin. Anti-Cancer Assoc. </source><volume>2010</volume>, <fpage>87</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1109/ICBBE.2010.5516957</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
